



Europäisches Patentamt  
European Patent Office  
Office européen des brevets

Publication number

0 156 433  
A2



(12)

## EUROPEAN PATENT APPLICATION

(21) Application number: 85200384.7

(51) Int. Cl. 4: C 07 D 237/20  
C 07 D 237/22, C 07 D 237/24  
C 07 D 401/04, C 07 D 401/12  
C 07 D 401/14, C 07 D 403/04  
C 07 D 403/12, C 07 D 417/12  
C 07 D 409/14, A 61 K 31/50

(22) Date of filing: 15.03.85

(30) Priority: 26.03.84 US 593444  
15.02.85 US 702772

(71) Applicant: JANSEN PHARMACEUTICA N.V.  
Turnhoutsebaan 30  
B-2340 Beerse(BE)

(43) Date of publication of application:  
02.10.85 Bulletin 85/40

(72) Inventor: Stokbroekx, Raymond Antoine  
Rode Kruisstraat 13  
B-2340 Beerse(BE)

(84) Designated Contracting States:  
AT BE CH DE FR GB IT LI LU NL SE


(72) Inventor: van der Aa, Marcel Jozef Maria  
Kattenberg 139  
B-2469 Kasterlee(BE)

(72) Inventor: Willems, Joannes Josephus Maria  
Tweesprongdreef 4  
B-2360 Oud-Turnhout(BE)


(72) Inventor: Luyckx, Marcel Gerebernus Maria  
Eksterstraat 24  
B-2440 Geel(BE)

(54) Anti-virally active pyridazinamines.

(57) Pyridazinamines of the formula



and their pharmaceutically acceptable acid addition salts and/or possible stereochemically isomeric forms and/or tautomeric forms for use as medicines in particular for use as anti-viral agents; pharmaceutical compositions containing such compounds as an active ingredient and a method of preparing such compositions; novel pyridazinamines of the formula



and a method of preparing said compounds

EP 0 156 433 A2

5

10

15

ANTI-VIRALLY ACTIVE PYRIDAZINAMINES

---

Background of the invention:

The present invention is concerned with anti-viral agents, 20 pharmaceutical compositions containing these agents and methods of treating warm-blooded animals suffering from viral diseases.

Viral infections are generally taught to be responsible for a number of diseases of various nature such as, for example, rabies, hepatitis, herpes, common cold, etc... More particularly, the latter 25 disease is widely spread throughout the world and is a major cause of sickness and absence from work. An agent capable of treating said disease would be a great benefit to mankind and certainly be of great economic importance.

Up until now no such agents are available and there exists no 30 established chemotherapeutic agent against the said disease.

The present invention discloses the useful anti-viral properties of a number of pyridazine derivatives and their use in the treatment of viral diseases. Some of the pyridazinamines of the present

35

-2-

invention are known in the art as intermediates for the synthesis of other useful compounds or as compounds having certain pharmacological properties. These compounds and a number of structurally closely related compounds can be found in the following references.


5 In J. Med. Chem. 24, 59-63 (1981) there are described a number of 1H-imidazolyl-pyridazines, while in European Patent Number 55,583, U.S. Patent Numbers 4,110,450, 4,104,385 and 2,985,657 a number of piperazinyl, pyrrolidinyl and piperidinyl substituted pyridazines are described as intermediates. In European Patent Number 9,655 3-chloro-  
 10 6-[4-(2-methoxyphenyl)-1-piperazinyl]pyridazine and 1-chloro-4-(4-hydroxypiperidino)phtalazine are also described as intermediates. Moreover a number of substituted 1-piperazinyl-pyridazines are described in J. Med. Chem. 6, 541-4 (1963), in ibid. 8, 104-107 (1965) and ibid. 15, 295-301 (1972) as compounds having adrenolytic, anti-  
 15 histaminic or analgesic activity.

The compounds of the present invention differ from the cited prior-art compounds by the specific substitution on the pyridazine moiety and particularly by their useful anti-viral properties.

20 Description of the preferred embodiments:

According to the present invention, there are provided anti-virally active pyridazinamines which may structurally be represented by the formula

25



the pharmaceutically acceptable acid-addition salts and/or possible  
 30 stereochemically isomeric forms and/or possible tautomeric forms thereof, wherein



<sup>1</sup> R¹ is a member selected from the group consisting of hydrogen, halo, 1H-imidazol-1-yl, lower alkyloxy, aryloxy, aryllower alkyl, lower alkylthio, arylthio, hydroxy, mercapto, amino, lower alkylsulfinyl, lower alkylsulfonyl, cyano, lower alkyloxycarbonyl, lower

-3-

alkylcarbonyl, and lower alkyl;

$R^2$  and  $R^3$  are, each independently, members selected from the group consisting of hydrogen and lower alkyl, or  $R^2$  and  $R^3$  combined may form a bivalent radical of formula  $-CH=CH-CH=CH-$ ;

5 A is a bivalent radical of formula:



wherein one of the hydrogen atoms within the radical  $C_m H_{2m}$ ,  $C_{m-1} H_{2(m-1)}$  or  $C_n H_{2n}$  may be replaced by lower alkyl or aryl;

20 m and n are, each independently, integers of from 1 to 4 inclusive, the sum of m and n being 3, 4 or 5;

$R^4$  is a member selected from the group consisting of hydrogen; lower alkyl; aryl; thiazolyl; pyrimidinyl; quinolinyl; lower alkylcarbonyl; lower alkyloxycarbonyl; aryllower alkyl; diaryllower alkyl; phenyl being substituted with arylcarbonyl; pyridinyl, being 25 optionally substituted with cyano or lower alkyl; cyclohexyl and cyclohexenyl both being optionally substituted with up to two substituents independently selected from the group consisting of cyano and aryl;

$R^5$  is hydrogen; lower alkyl; aryl; hydroxy; lower alkyloxy; 30 aryloxy; lower alkyloxy being substituted with morpholine, pyrrolidine or piperidine; amino; (lower alkyloxycarbonyl)amino; arylamino; (aryl)(lower alkyl)amino; (aryllower alkyl)amino; (aryllower alkenyl)amino; (aryllower alkenyl)(lower alkyl)amino; arylcarbonyloxy;

$R^6$  is hydrogen; aryl; lower alkyl; (lower alkylcarbonyl 35 amino)lower alkyl, aryllower alkyl; arylcarbonyllower alkyl;

aminocarbonyl; arylcarbonyl; arylaminocarbonyl; (aryllower alkyl)carbonyl, lower alkyloxycarbonyl; indolyl; pyridinyl;  
 7      8  
 $R^7$  and  $R^8$  are, each independently, members selected from the group consisting of hydrogen, lower alkyl, aryl, aryllower alkyl and  
 5      pyridinyl;

wherein aryl is phenyl, being optionally substituted with up to 3 substituents, each independently selected from the group consisting of halo, lower alkyl, trifluoromethyl, nitro, amino, lower alkyloxy, hydroxy and lower alkyloxycarbonyl; thienyl; and naphthalenyl.


10

As used in the foregoing definitions the term halo is generic to fluoro, chloro, bromo and iodo; "lower alkyl" is meant to include straight and branched saturated hydrocarbon radicals, having from 1 to 6 carbon atoms, such as, for example, methyl, ethyl, 1-methylethyl, 15 1,1-dimethylethyl, propyl, butyl, pentyl, hexyl and the like; "lower alkenyl" refers to alkenyl radicals having from 2 to about 6 carbon atoms, such as, for example, 2-propenyl, 2-but enyl, 3-but enyl, 2-pentenyl and the like.

20

The compounds of formula (I) can generally be prepared by N-alkylating an amine of formula (II) with a reagent of formula (III) following art-known N-alkylating procedures.

25



30


In (III) W represents an appropriate reactive leaving group such as, for example, halo, i.e. fluoro, chloro, bromo or iodo, or a sulfonyloxy group, e.g. methylsulfonyloxy or 4-methylphenylsulfonyloxy, a lower alkyloxy or lower alkylthio group.

The alkylation reactions can conveniently be conducted in an inert 35 organic solvent such as, for example, an aromatic hydrocarbon, e.g.,

-5-

benzene, methylbenzene, dimethylbenzene, and the like; a lower alkanol, e.g., methanol, ethanol, 1-butanol and the like; a ketone, e.g., 2-propanone, 4-methyl-2-pentanone and the like; an ether, e.g., 1,4-dioxane, 1,1'-oxybisethane, tetrahydrofuran and the like; a 5 dipolar aprotic solvent such as, for example, N,N-dimethylformamide (DMF); N,N-dimethylacetamide (DMA); dimethyl sulfoxide (DMSO); nitrobenzene; 1-methyl-2-pyrrolidinone; and the like. The addition of an appropriate base such as, for example, an alkali metal carbonate or hydrogen carbonate, sodium hydride or an organic base such as, for 10 example, N,N-diethylethanamine or N-(1-methylethyl)-2-propanamine may be utilized to pick up the acid which is liberated during the course of the reaction. In some circumstances the addition of an iodide salt, preferably an alkali metal iodide, is appropriate. The alkylation reactions can also be conducted by mixing and/or melting the reactants 15 together, optionally in the presence of the bases mentioned hereinabove. Somewhat elevated temperatures may be used to enhance the rate of the reaction.

The compounds of formula (I) can also be converted into each other  
20 by an appropriate functional groupstransformation reaction.  
For example, the compounds of formula (I), wherein A is a radical of  
formula (b) wherein R<sup>4</sup> is a hydrogen radical, said compounds being  
represented by the formula (I-a), may be alkylated or acylated with a  
reagent of formula (IV) following the procedures described hereinabove  
25 for the preparation of (I) starting from (II) and (III), thus  
obtaining a compound of formula (I-b).




-6-

In (IV), W has the previously defined meaning, and R<sup>4-a</sup> is as R<sup>4</sup>, provided that it is not hydrogen.

The compounds of formula (I), wherein A is a radical of formula (b), wherein R<sup>4</sup> is lower alkyl, aryl lower alkyl, diaryl lower alkyl, 5 cyclohexyl or cyclohexenyl, said R<sup>4</sup> being represented by R<sup>4-b</sup> and said compounds by the formula (I-c), may be prepared by reductively N-alkylating a compound of formula (I-a) with an appropriate carbonyl-compound of formula (R<sup>4-b-1</sup>)=C=O, said (R<sup>4-b-1</sup>)=C=O being a compound of formula R<sup>4-b</sup>-H, wherein a -CH<sub>2</sub>-radical is oxidized to 10 a carbonyl radical.

15



Said reductive N-alkylation reaction may conveniently be carried out by catalytically hydrogenating a stirred and heated mixture of the reactants in a suitable reaction-inert organic solvent according to 20 art-known catalytic hydrogenating procedures. The reaction mixture may be stirred and/or heated in order to enhance the reaction rate. Suitable solvents are, for example, water; lower alkanols, e.g. methanol, ethanol, 2-propanol and the like; cyclic ethers, e.g. 1,4-dioxane and the like; halogenated hydrocarbons, e.g. trichloro-25 methane and the like; N,N-dimethylformamide; dimethyl sulfoxide and the like; or a mixture of 2 or more of such solvents. The term "art-known catalytic hydrogenating procedures" means that the reaction is carried out under hydrogen atmosphere and in the presence of an appropriate catalyst such as, for example, palladium-on-charcoal, 30 platinum-on-charcoal and the like. In order to prevent the undesired further hydrogenation of certain functional groups in the reactants and the reaction products it may be advantageous to add an appropriate catalyst-poison to the reaction mixture, e.g., thiophene and the like.

The compounds of formula (I), wherein A is a radical of formula

35

-7-

(b), wherein R<sup>4</sup> is hydrogen can be converted into the corresponding compounds wherein R<sup>4</sup> is an optionally substituted 2-cyclohexenyl radical, by reacting the former compounds with an appropriate cyclohexanone derivative in the presence of a suitable solvent such as, for example, a hydrocarbon, e.g. benzene, methylbenzene and the like. In some cases it may be advantageous to supplement the reaction mixture with an appropriate acid, e.g. 4-methylsulfonic acid and the like.

Or, conversely, the compounds of formula (I), wherein A is a radical of formula (b) wherein R<sup>4</sup> is lower alkyloxycarbonyl or lower alkylcarbonyl may be deacylated following art-known procedures, e.g. by reacting the starting compounds with an appropriate acidic or basic solution.

Similarly, the compounds of formula (I) wherein A is a radical of formula (c) wherein R<sup>5</sup> is (lower alkyloxycarbonyl)amino may be converted into the corresponding amino-compounds.

The compounds of formula (I) wherein A is a radical of formula (c) wherein R<sup>5</sup> is hydroxy can be converted into the corresponding compounds of formula (I) wherein A is a radical of formula (d) by an elimination reaction. This can be accomplished by reacting the former compounds with a suitable acidic solution preferably at higher temperatures. Suitable acidic solutions contain one or more acids such as sulfuric, hydrochloric, acetic and the like acids in admixture with water and/or an organic solvent, such as methanol, ethanol and the like.

Or the starting hydroxy containing compounds can be reacted with an appropriate deshydratating agent such as, for example, phosphoryl chloride, thionyl chloride, phosphor trichloride, preferably in the presence of a suitable solvent such as, for example, pyridine.

30 N,N-dimethylformamide (DMF) and the like.

The compounds of formula (I) containing a cyclohexenyl radical may be converted into the corresponding cyclohexyl containing compounds by an appropriate reduction procedure, e.g. by reacting the former compounds with a metal hydride, e.g. sodium borohydride, in a suitable

solvent, e.g. an alkanol such as methanol and the like, optionally in the presence of a base, e.g. sodium methoxide and the like.

The compounds of formula (I), wherein R<sup>1</sup> is halo may be converted into the corresponding compounds wherein R<sup>1</sup> is lower

- 5 alkyloxy, aryloxy, aryllower alkyloxy, lower alkylthio or arylthio by reacting the said halo containing compounds with an appropriate aromatic or aliphatic alcohol or mercaptane. The said reaction may be conducted in an appropriate solvent such as, for example a ketone, e.g. 2-propanone, DMF, DMA and the like solvents. The addition of a  
10 suitable base such as, for example, an alkali metal hydride, e.g. sodium hydride, an alkali metal carbonate, e.g. sodium carbonate may be used to enhance the rate of the reaction. Alternatively, the starting halo compounds may be reacted with an appropriate alkali metal alkoxide, aryloxide or (aryl substituted)alkoxide in a suitable  
15 solvent, preferably in the corresponding alcohol, thus preparing the desired compounds of formula (I) wherein R<sup>1</sup> is lower alkyloxy, aryloxy and aryllower alkyloxy.

The compounds of formula (I) wherein R<sup>1</sup> is arylmethylgxy may be converted into the corresponding hydroxy compounds following art-known  
20 procedures for the removal of the arylmethyl group, e.g. by reacting the starting compounds with an acidic solution or with hydrogen in the presence of an appropriate catalyst in a suitable solvent.

- 25 The compounds of formula (I), wherein R<sup>1</sup> is halo may be converted into the corresponding compounds wherein R<sup>1</sup> is hydrogen, following art-known hydrogenolysis procedures, i.e. by heating the starting compounds in a suitable solvent under hydrogen atmosphere in the presence of an appropriate catalyst, e.g. palladium-on-charcoal and the like catalysts.

The compounds of formula (I), wherein R<sup>1</sup> is halo may further be  
30 converted into the corresponding mercapto containing compounds by reacting the former compounds with hydrogen sulfide or a reagent capable of generating hydrogen sulfide, e.g. thiourea in the presence of a base.

The compounds of formula (I) wherein R<sup>1</sup> is lower alkyloxy-

-9-

carbonyl may be converted into the corresponding lower alkylcarbonyl compounds by reacting the starting compounds with an appropriate ester in the presence of an alkali metal in a suitable alcohol.


The compounds of formula (I) have basic properties and,

5 consequently, they may be converted to their therapeutically active non-toxic acid-addition salt forms by treatment with appropriate acids, such as, for example, inorganic acids, such as hydrohalic acid, e.g. hydrochloric, hydrobromic and the like, and sulfuric acid, nitric acid, phosphoric acid and the like; or organic acids, such as, for example, acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, 10 2-oxopropanoic, ethanedioic, propanedioic, butanedioic, (Z)-2-butene-dioic, (E)-2-butenedioic, 2-hydroxybutanedioic, 2,3-dihydroxybutane-dioic, 2-hydroxy-1,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic, 15 cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic and the like acids. Conversely the salt form can be converted by treatment with alkali into the free base form.


A number of intermediates and starting materials in the foregoing preparations are known compounds which may be prepared according to art-known methodologies as described, for example, in U.S. Patent Numbers 2,997,472; 2,979,507; 2,997,474 and 3,002,976.

The intermediates of formula (II), wherein A is a radical of formula (b), wherein R<sup>4</sup> is other than hydrogen, said R<sup>4</sup> being represented by R<sup>4-a</sup> and said intermediates by the formula (II-a), may be prepared by alkylating an amine of formula (V) with a reagent of formula (IV), thus yielding an intermediate of formula (VI), and subsequently eliminating the group P. In (V) and (VI) P is an appropriate protective group such as, for example, lower alkyloxy-carbonyl, arylmethoxycarbonyl, arylmethyl, arylsulfonyl and the like. The elimination of P in (VI) may generally be carried out following art-known procedures such as, for example, by hydrolysis in alkaline or acidic medium.

-10-



The intermediates of formula (VI) may also be prepared by  
15 N-alkylating an amine of formula (VII) with a reagent of formula  
(VIII), following art-known N-alkylating procedures.




25 The reaction of (IV) with (V) and of (VII) with (VIII) may be conducted following the same procedures described hereinabove for the preparation of (I) starting from (II) and (III).

The intermediates of formula (II), wherein A is a radical of formula (c), wherein R<sup>6</sup> is hydrogen and R<sup>5</sup> is a radical of formula -NR<sup>9,10</sup>R<sup>10</sup>, said -NR<sup>9,10</sup>R<sup>10</sup> being arylamino, (aryl)(lower alkyl)-amino, (aryllower alkyl)amino, (aryllower alkenyl)(lower alkyl)amino, (aryllower alkenyl)amino, said intermediates being represented by the formula (II-b), can conveniently be prepared by reductively N-alkylating a ketone of formula (IX) with an amine of formula (X), thus yielding an intermediate of formula (XI), and subsequently

-11-

eliminating the protective group P. In (IX) and (XI), P has the previously described meaning.



15 The said reductive amination may conveniently be carried out by catalytically hydrogenating a mixture of the reactants in a suitable reaction-inert medium, according to art-known procedures.

The intermediates of formula (II), wherein A is a bivalent radical of formula (c) wherein R<sup>5</sup> is hydroxy and R<sup>6</sup> is aryl, lower alkyl or substituted lower alkyl can be prepared by reacting (IX) with an appropriate Grignard reagent in a suitable solvent. The thus obtained hydroxy containing intermediates may be deprotected or further reacted with a suitable acidic solution in order to eliminate a water molecule and subsequently be deprotected thus preparing intermediates of formula (II) wherein A is a radical of formula (d).

The compounds of formula (I) show anti-viral activity and are particularly attractive due to their favourable therapeutic index, resulting from an acceptable low degree of cell toxicity, combined with a desirable anti-viral activity at low doses.

The useful anti-viral properties of the compounds of formula (I) are demonstrated in the following test procedure.

### Rhinovirus Cytopathic Effect Test

35 Rhinovirus-sensitive HeLa cells were seeded into Minemal Essential

-12-

Medium (MEM) supplemented with 5% inactivated foetal calf serum and non essential amino acids. The seeded cells were incubated overnight at 37°C in a 5% CO<sub>2</sub> atmosphere. After 24 hours the cells were treated with solutions of the test compounds in a solvent containing 1 part by volume of DMSO and 7 parts by volume of MEM supplemented with 5 10% inactivated calf serum, or with the said solvent.

Both the solvent and drug treated cells were incubated for 3 hours at 37°C and subsequently a standardized inoculum of human rhinovirus was added. During a further incubation period at 33°C, the rhinovirus was 10 allowed to grow in the Hela cells. Scoring of the results was delayed until a complete (100%) cytopathic effect was obtained in the virus controls (cells treated with solvent and virus).

Anti-viral activity was scored as the lowest concentration of the tested drug in µg/ml inhibiting at least 75% of the cytopathic 15 effect observed in the virus controls.

Additionally, some of the compounds of the present invention show also analgetic and antitussive properties which properties can be demonstrated, for example by the Tail Withdrawal Reflex test and the 20 Writting Test described in Arzneim. Forsch., 25, 1505-1509 (1975) and in Arzneim. Forsch., 15, 107-117 (1965).

In view of their useful pharmacological properties, the compounds of formula (I) and their acid-addition salts are very useful in the treatment of viral diseases.

25 In order to enhance the ease of administration, the subject compounds may be formulated into various pharmaceutical forms. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, in base or acid-addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier 30 may take a wide variety of forms depending on the form of preparation desired for administration.

These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally, percut-

-13-

aneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as 5 suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case 10 solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose 15 solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents, and the like may be employed.

In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a 20 suitable wettable agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be 25 administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment.


Acid addition salts of (I) due to their increased water solubility over the corresponding base form, are obviously more suitable in the preparation of aqueous compositions.

30 It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a

predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, 5 wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.

In a further aspect of the present invention there is provided a method of treating viral diseases in warm-blooded animals suffering from said viral diseases, which method comprises the systemic administration to warm-blooded animals of an anti-virally effective amount of a compound of formula (I), a pharmaceutically acceptable acid addition salt, a possible stereoisomeric or tautomeric form thereof. Suitable doses administered daily to subjects are varying from 0.01 mg to 1 g, preferably from 1 mg to 500 mg.

15 Preferred methods of treating viral diseases in warm-blooded animals suffering from said viral diseases, are those methods comprising the systemic administration to warm-blooded animals of an anti-virally effective amount of a compound having the formula



25 a pharmaceutically acceptable acid-addition salt and/or a possible  
stereoisomeric and/or a tautomeric form thereof, wherein R<sup>1</sup>, R<sup>2</sup>  
and R<sup>3</sup> have the previously defined meaning and A<sup>1</sup> is a bivalent  
radical having the formula (a), (b), (c) or (d);

provided that

provided that

30 i) when  $R^1$ ,  $R^2$  and  $R^3$  are hydrogen radicals and  $A^1$  is a radical of formula (b), then  $R^4$  is other than 3,3-diphenylpropyl;


ii) when  $R^1$  is hydrogen and  $R^2$  and  $R^3$  combined form a bivalent  $CH=CH-CH=CH$  radical, then  $-N \cdot A^1$  is other than piperidinyl;

35 iii) when  $R^1$  is halo,  $R^2$  is lower alkyl and  $R^3$  is hydrogen, then  $-N \cdot A^1$  is other than piperidinyl and hexahydro-1H-azepinyl.


iv) when  $R^1$  is chloro, and  $A^1$  is a bivalent radical of formula  
 (b) then  $R^4$  is other than (dimethoxyphenyl)methyl, (dimethoxyphenyl)ethyl,  $\alpha$ -methyl-phenethyl or (2-methylphenyl)methyl.

5 Preferred compositions within the invention are those comprising an inert carrier and an anti-virally effective amount of a compound of formula (I'), a pharmaceutically acceptable acid-addition salt and/or a possible stereochemically isomeric form and/or a tautomeric form thereof.

10 An additional feature of the present invention consists in the fact that some of the compounds of formula (I) and/ or the pharmaceutically acceptable acid-addition salts and/or possible stereochemically isomeric and/or the possible tautomeric forms thereof are new, which compounds are represented by the formula  
 15



20 wherein  $R^1$ ,  $R^2$  and  $R^3$  have the previously described meaning and  
 $A^2$  is a bivalent radical having the formula (a), (c), (d) or



25 wherein m and n have the previously described meaning and one of the hydrogen atoms within the radical  $\text{C}_{\text{m}}^{\text{H}}_{2\text{m}}$ ,  $\text{C}_{\text{m}-1}^{\text{H}}_{2(\text{m}-1)}$  or  $\text{C}_{\text{n}}^{\text{H}}_{2\text{n}}$  may be replaced by lower alkyl or aryl; and  
 $R^4-C$  is a member selected from the group consisting of aryl;  
 30 thiazolyl; pyrimidinyl; quinolinyl; lower alkylcarbonyl, lower alkyloxycarbonyl; aryllower alkyl; diaryllower alkyl; phenyl being substituted with arylcarbonyl; pyridinyl, being optionally substituted with cyano or lower alkyl; cyclohexyl and cyclohexenyl both being  
 35 optionally substituted with up to two substituents independently

selected from the group consisting of cyano and aryl; provided that

- 1) when  $A^2$  is a radical of formula (c) and  $R^6$  is hydrogen, then  
 $R^5$  is other than hydrogen, hydroxy or lower alkyl;
- ii) when  $R^1$ ,  $R^2$  and  $R^3$  are hydrogen radicals and  $A^2$  is a  
radical of formula (b-1), then  $R^{4-C}$  is other than  
3,3-diphenylpropyl;
- iii) when  $R^2$  and  $R^3$  are hydrogen radicals and  $A^2$  is a radical of  
formula (a), then  $R^1$  is other than halo;
- iv) when  $R^1$  is chloro,  $R^2$  and  $R^3$  are hydrogen radicals and  $A^2$   
is a radical of formula (b-1), then  $R^{4-C}$  is other than  
2-methoxyphenyl.
- v) when  $R^1$  is chloro, and  $A^2$  is a bivalent radical of formula  
(b-1) then  $R^{4-C}$  is other than (dimethoxyphenyl)methyl,  
(dimethoxyphenyl)ethyl,  $\alpha$ -methyl-phenethyl or (2-methylphenyl)-  
methyl.

Particularly preferred methods of treating viral diseases in  
warm-blooded animals suffering from same, are those methods comprising  
the systemic administration to warm-blooded animals of an anti-virally  
effective amount of a compound having the formula (I") a pharmaceuti-  
cally acceptable acid-addition salt and/or a possible stereochemically  
isomeric form and/or a possible tautomeric form thereof.

Particularly preferred compositions within the invention are those  
comprising an inert carrier and an anti-virally effective amount of a  
compound of formula (I"), a pharmaceutically acceptable acid-addition  
salt and/or a possible stereochemically isomeric form and/or a  
possible tautomeric form thereof.

Within the group of the said new compounds, those compounds of  
formula (I") are preferred wherein  $A^2$  is a bivalent radical of  
formula (b-1), wherein  $R^{4-C}$  is aryl, pyridinyl, pyrimidinyl, lower  
alkyloxycarbonyl, aryllower alkyl, diaryllower alkyl, quinolinyl, or  
wherein  $A^2$  is a bivalent radical of formula (c), wherein  $R^5$  is  
hydrogen, aryl, arylamino, (aryl)(lower alkyl)amino, hydroxy, indolyl  
and  $R^6$  is hydrogen, aryl, arylcarbonyl, (arylcarbonyl)lower alkyl,  
or wherein  $A^2$  is a bivalent radical of formula (d).

Particularly preferred new compounds are those wherein the

bivalent radical  $A^2$  is as defined for the preferred new compounds and wherein  $R^2$  and  $R^3$  are both hydrogen radicals.

More particularly preferred new compounds are those wherein  $R^2$ ,  $R^3$  and  $A^2$  are as defined for the particularly preferred compounds and wherein in the said bivalent radical  $A^2$  having the formula (b-1) 5  $m$  is the integer 2 or 3 and  $n$  is 2, in the radical  $A^2$  having the formula (c)  $m$  is the integer 1 or 2 and  $n$  is the integer 2, and in the radical  $A^2$  of formula (d),  $m$  is the integer 1 or 2 and  $n$  is the integer 2.

10 Especially preferred new compounds are those wherein  $R^2$ ,  $R^3$ ,  $A^2$ ,  $m$  and  $n$  are as defined for the previously mentioned more particularly preferred new compounds and wherein  $R^1$  is halo, lower alkyloxy, aryloxy, lower alkylthio, arylthio and cyano.

15 More especially preferred new compounds are those wherein  $R^2$ ,  $R^3$ ,  $A^2$ ,  $m$  and  $n$  are as defined for the previously mentioned more particularly preferred new compounds, and wherein  $R^1$  is halo.

The most preferred compounds within the invention are selected from the group consisting of 3-bromo-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine, 3-chloro-6-[3,6-dihydro-4-(3-methylphenyl)-1(2H)-20 pyridinyl]pyridazine and the pharmaceutically acceptable acid-addition salts thereof.

Some of the compounds of this invention may have several asymmetric centra in their structure. Pure stereoisomeric forms of the compounds of formula (I) may be obtained by art-known separation 25 procedures. For example, diastereomers may be separated by selective crystallization or by application of chromatographic techniques, while enantiomers may be separated by the selective crystallization of their diastereomeric salts with optically active acids. Pure stereoisomeric forms may also be obtained by stereospecific syntheses starting from 30 the corresponding stereoisomerically pure forms of the appropriate starting materials. Stereochemically isomeric forms of the compounds of formula (I) are intended to be embraced within the scope of this invention.

The following examples are intended to illustrate and not to limit 35 the scope of the present invention in all its aspects. Unless otherwise stated all parts therein are by weight.

EXAMPLESA. Preparation of Intermediates.Example 1

A mixture of 221 parts of 4-fluorobenzeneacetonitrile, 700 parts of sodium methoxide solution 30% and 900 parts of dimethylbenzene was stirred for 5 minutes. Then there were added dropwise 309 parts of methyl 2-propenoate (exothermic reaction: temperature rose to 65°C). Upon completion, stirring was continued overnight at reflux temperature. The methanol was distilled off till an internal temperature of 110°C was reached. After cooling, 1000 parts of a hydrochloric acid solution 6N were added dropwise and the whole was stirred and refluxed for 5 minutes. Upon cooling, the layers were separated. The organic phase was dried, filtered and evaporated. The residue was stirred and refluxed for 4 hours together with 500 parts of acetic acid, 500 parts of water and 500 parts of a hydrochloric acid solution. After cooling, the product was extracted with trichloromethane. The extract was washed successively with water, with a diluted sodium hydroxide solution and again with water till neutralization. dried, filtered and evaporated. The residue was crystallized from 2-propanol, yielding 134.5 parts of 1-(4-fluorophenyl)-4-oxocyclohexanecarbonitrile; mp. 91.8°C (intermediate 1).

Example 2

A mixture of 17.6 parts of 1-(phenylmethyl)piperazine, 8.4 parts of ethyl 4-fluorobenzoate and 45 parts of N,N-dimethylacetamide was stirred and refluxed for 22 hours. The reaction mixture was cooled and poured onto 500 parts of water. The product was extracted three times with benzene. The combined extracts were washed three times with a lot of water, dried, filtered and evaporated. The residue was stirred in hexane. The product was filtered off, washed with hexane and dried in vacuo, yielding 12.5 parts (77%) of ethyl 4-[4-(phenylmethyl)-1-piperazinyl]benzoate (intermediate 2).

Example 3

A mixture of 14 parts of ethyl 4-(methylamino)-1-piperidine-carboxylate, 13 parts of (3-chloro-1-propenyl)benzene, 26.5 parts of sodium carbonate and 240 parts of 4-methyl-2-pentanone was stirred and

-19-

refluxed over week-end using a water separator. The reaction mixture was cooled, water was added and the layers were separated. The organic phase was dried, filtered and evaporated. The residue was converted into the ethanedioate salt in 2-propanol and 2-propanone. The salt was 5 filtered off and dried, yielding 23.4 parts of (E)-ethyl 4-[methyl(3-phenyl-2-propenyl)amino]-1-piperidinecarboxylate ethanedioate (1:1); mp. 160.2°C (intermediate 3).

Example 4

To a stirred mixture of 19 parts of 1-(phenylmethyl)-4-piperidinol, 10 15.2 parts of N,N-diethylethanamine and 180 parts of methylbenzene were added dropwise (slowly) 14 parts of benzoyl chloride. Upon completion, stirring was continued for 3 hours at room temperature. The formed hydrochloride salt of benzoyl chloride was filtered off and washed with methylbenzene. The filtrate was evaporated. The oily residue was 15 purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (95:5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was converted into the hydrochloride salt in 2-propanol. The salt was filtered off and dried, yielding 18 parts (54%) of [1-(phenylmethyl)- 20 4-piperidinyl] benzoate hydrochloride; mp. 225.9°C (intermediate 4).

Example 5

To a stirred mixture of 7.8 parts of sodium amide 5% in benzene and 135 parts of methylbenzene was added dropwise a solution of 11.7 parts of benzeneacetonitrile in 45 parts of methylbenzene at 25°C (cooling 25 was necessary). After stirring for 30 minutes at 30°C, there was added dropwise a solution of 24.7 parts of ethyl 1-(phenylmethyl)-4-piperidinecarboxylate in 45 parts of methylbenzene at 30°C. Upon completion, stirring was continued overnight at 80°C. The reaction mixture was cooled, 12 parts of ethanol were added and the whole was poured into 30 ice water. The layers were separated and the aqueous phase was neutralized with acetic acid. The oily product was extracted with trichloromethane. The extract was dried, filtered and evaporated. The residue was crystallized from 4-methyl-2-pentanone, yielding 12 parts (38%) of  $\alpha$ -[hydroxy[1-(phenylmethyl)-4-piperidinyl]methylidene]- 35 benzeneacetonitrile; mp. 191.9°C (intermediate 5).

-20-

To 200 parts of water were added carefully 200 parts of acetic acid while stirring and cooling. Then there were added dropwise (slowly) 368 parts of sulfuric acid. 90 Parts of  $\alpha$ -[hydroxy[1-(phenylmethyl)-4-piperidinyl]methylidene]benzeneacetonitrile were added and the whole was stirred and refluxed overnight. The acetic acid was evaporated and the residue was poured into crushed ice. The mixture was alkalized with concentrate ammonium hydroxide and the oily product was extracted with trichloromethane. The extract was dried, filtered and evaporated, yielding 79 parts (96.3%) of 2-phenyl-1-[1-(phenylmethyl)-4-piperidinyl]ethanone as a residue (intermediate 6).

Example 6

A mixture of 93 parts of N-(2-chloroethyl)-N-(3-chloropropyl)-4-methylbenzenesulfonamide, 30.3 parts of 2,3-dimethylbenzenamine, 63.6 parts of sodium carbonate, 1 part of potassium iodide and 240 parts of cyclohexanol was stirred and refluxed over weekend using a water separator. After cooling, the reaction mixture was poured into water. The product was extracted with methylbenzene. The extract was washed twice with water, dried, filtered and evaporated. The residue was crystallized from 2-propanol and a small amount of tetrahydrofuran. The product was filtered off and dried, yielding 47.8 parts (53.3%) of 1-(2,3-dimethylphenyl)hexahydro-4-[(4-methylphenyl)sulfonyl]-1H-1,4-diazepine; mp. 86.2°C (intermediate 7).

In a similar manner there were also prepared:

1-[2-methoxy-5-(trifluoromethyl)phenyl]piperazine hydrochloride; mp. 226.8°C (intermediate 8);

1-[(4-methylphenyl)sulfonyl]-4-(2,4,6-trimethylphenyl)piperazine (intermediate 9);

1-(3,5-dichlorophenyl)hexahydro-4-[(4-methylphenyl)sulfonyl]-1H-1,4-diazepine (intermediate 10);

1-(3-chlorophenyl)hexahydro-4-[(4-methylphenyl)sulfonyl]-1H-1,4-diazepine; mp. 116.6°C (intermediate 11);

hexahydro-1-(2-methoxyphenyl)-4-[(4-methylphenyl)sulfonyl]-1H-1,4-diazepine as a residue (intermediate 12); and

hexahydro-1-[(4-methylphenyl)sulfonyl]-4-[3-(trifluoromethyl)phenyl]-1H-1,4-diazepine as a residue (intermediate 13).

-21-

Example 7

To a stirred mixture of 180 parts of 1-[(4-methylphenyl)sulfonyl]-4-(2,4,6-trimethylphenyl)piperazine and 450 parts of water were added dropwise 675 parts of sulfuric acid. The whole was stirred and refluxed 5 for 4 hours. After cooling, the whole was treated with an ammonium hydroxide solution. The product was extracted with dichloromethane. The extract was dried, filtered and evaporated, yielding 70 parts (69%) of 1-(2,4,6-trimethylphenyl)piperazine as a residue (intermediate 14).

In a similar manner there were also prepared:

10      4-(3-methylphenyl)-4-piperidinocarboxamide (intermediate 15);  
1-(2,3-dimethylphenyl)hexahydro-1H-1,4-diazepine as a residue  
(intermediate 16);

hexahydro-1-(2-methoxyphenyl)-1H-1,4-diazepine monohydrochloride;  
mp. 176.6°C (intermediate 17); and

15      hexahydro-1-[3-(trifluoromethyl)phenyl]-1H-1,4-diazepine  
monohydrochloride; mp. 191.1°C (intermediate 18).

Example 8

A mixture of 7.9 parts of ethyl 3-oxo-1-pyrrolidinecarboxylate, 5.35 parts of 3-methylbenzenamine, 1 part of a solution of thiophene in 20 methanol 4% and 200 parts of methanol was hydrogenated at normal pressure and at 50°C with 2 parts of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated, yielding 12.4 parts (100%) of ethyl 3-[(3-methylphenyl)amino]-1-pyrrolidinecarboxylate as 25 a residue (intermediate 19).

In a similar manner there were also prepared:

N-(2,3-dimethylphenyl)-1-(phenylmethyl)-3-piperidinamine  
ethanedioate(1:1); mp. 151.6°C (intermediate 20);

N-phenyl-1-(phenylmethyl)-3-piperidinamine as a residue  
30 (intermediate 21);

ethyl 3-[(2,3-dimethylphenyl)amino]-1-pyrrolidinecarboxylate as a  
residue (intermediate 22);

ethyl 4-[[3-(trifluoromethyl)phenyl]amino]-1-piperidinocarboxylate  
monohydrochloride (intermediate 23);

N-(3-methylphenyl)-1-(phenylmethyl)-3-piperidinamine as a residue (intermediate 24); and ethyl 3-[(3-(trifluoromethyl)phenyl]amino]-1-pyrrolidinecarboxylate as a residue (intermediate 25).

5    Example 9

To a stirred solution of 152 parts of 3-methyl-1-(phenylmethyl)-4-piperidinone in 900 parts of methylbenzene were added dropwise 218 parts of ethyl carbonochloride at room temperature. Upon completion, stirring was continued overnight at reflux. After cooling, the reaction mixture was washed with water and hydrochloric acid, dried, filtered and evaporated. The residue was distilled, yielding 120.5 parts (83%) of ethyl 3-methyl-4-oxo-1-piperidinecarboxylate; bp. 98-105°C at 1 mm Hg pressure (intermediate 26).

Example 10

15    To a stirred and refluxed Grignard complex previously prepared starting from a mixture of 4.2 parts of 1-bromo-3-chlorobenzene, 5.4 parts of magnesium and 135 parts of tetrahydrofuran were added dropwise 19 parts of 1-(phenylmethyl)-3-piperidinone. Upon completion, stirring was continued for 1 hour at reflux temperature. After cooling, the reaction mixture was poured into ice water and 12.5 parts of acetic acid. The layers were separated. The aqueous phase was extracted with trichloromethane. The organic layer was washed with water, dried, filtered and evaporated. The residue was converted into the hydrochloride salt in 2-propanol. The salt was filtered off and dried, yielding 26 parts (76%) of 3-(3-chlorophenyl)-1-(phenylmethyl)-3-piperidinol hydrochloride (intermediate 27).

In a similar manner there were also prepared:

ethyl 4-hydroxy-4-(2-thienyl)-1-piperidinecarboxylate; mp. 146.2°C; (intermediate 28):

30    ethyl 4-hydroxy-4-(1-naphthalenyl)-1-piperidinecarboxylate; mp. 109.2-114.8°C; (intermediate 29);

ethyl 3-(4-chloro-3-(trifluoromethyl)phenyl]-3-hydroxy-1-pyrrolidinecarboxylate as a residue; (intermediate 30);

35    ethyl 4-hydroxy-4-(2-naphthalenyl)-1-piperidinecarboxylate as a residue; (intermediate 31);

-23-

3-(3-methylphenyl)-1-(phenylmethyl)-3-piperidinol hydrochloride  
(intermediate 32);

cis-3-methyl-4-(3-methylphenyl)-1-(phenylmethyl)-4-piperidinol as a residue (intermediate 33);

5 ethyl cis-4-(3-fluorophenyl)-4-hydroxy-3-methyl-1-piperidinecarboxylate as a residue (intermediate 34);

ethyl cis-4-hydroxy-3-methyl-4-(2-thienyl)-1-piperidinecarboxylate as a residue (intermediate 35);

10 ethyl 3-hydroxy-3-(2-thienyl)-1-piperidinecarboxylate  
(intermediate 36);

3-(3-fluorophenyl)-1-(phenylmethyl)-3-piperidinol hydrochloride  
(intermediate 37);

ethyl 4-(2,3-dimethylphenyl)-4-hydroxy-1-piperidinecarboxylate  
(intermediate 38);

15 3-(2,3-dimethylphenyl)-1-(phenylmethyl)-3-piperidinol hydrochloride  
(intermediate 39);

3-(3-methylphenyl)-1-(phenylmethyl)-3-pyrrolidinol hydrochloride  
(intermediate 40);

20 ethyl 3-[4-chloro-3-(trifluoromethyl)phenyl]-3-hydroxy-1-piperidinecarboxylate as a residue (intermediate 41);

3-(3-fluorophenyl)-1-(phenylmethyl)-3-pyrrolidinol hydrochloride  
(intermediate 42);

ethyl 4-hydroxy-4-(3-methoxyphenyl)-3-methyl-1-piperidinecarboxylate as a residue (intermediate 43); and

25 3-(3-methoxyphenyl)-1-(phenylmethyl)-3-pyrrolidinol hydrochloride  
(intermediate 44).

Example 11

A mixture of 7 parts of 3-(2,3-dimethylphenyl)-1-(phenylmethyl)-3-piperidinol hydrochloride and 200 parts of a hydrochloric acid solution 6N was stirred and refluxed overnight. The reaction mixture was evaporated. Water was added and the base was liberated with ammonium hydroxide. The product was extracted with trichloromethane. The extract was washed with water, dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (98:2 by volume) as eluent.

-24-

The first fraction was collected and the eluent was evaporated, yielding 0.7 parts (12%) of 5-(2,3-dimethylphenyl)-1,2,3,4-tetrahydro-1-(phenylmethyl)pyridine as a residue (intermediate 45).  
The second fraction was collected and the eluent was evaporated, yielding 5.3 parts (91%) of 5-(2,3-dimethylphenyl)-1,2,3,6-tetrahydro-1-(phenylmethyl)pyridine as a residue (intermediate 46).

Example 12

A mixture of 8 parts of 3-(3-methylphenyl)-1-(phenylmethyl)-3-pyrrolidinol hydrochloride and 150 parts of a hydrochloric acid solution 6N was stirred and refluxed for 3 hours. After cooling, the reaction mixture was evaporated, yielding 7.4 parts (100%) of 2,3-dihydro-4-(3-methylphenyl)-1-(phenylmethyl)-1H-pyrrole hydrochloride as a residue (intermediate 47).

In a similar manner there were also prepared:

15 1,2,3,6-tetrahydro-5-(3-methylphenyl)-1-(phenylmethyl)pyridine as a residue (intermediate 48); and  
5-(3-fluorophenyl)-1,2,3,6-tetrahydro-1-(phenylmethyl)pyridine hydrochloride (intermediate 49).

Example 13

20 To a stirred solution of 13 parts of 3-(3-chlorophenyl)-1-(phenylmethyl)-3-piperidinol in 270 parts of methylbenzene were added dropwise 10.9 parts of ethyl carbonochloridate at room temperature. Upon completion, stirring was continued overnight at reflux temperature. After cooling to room temperature, the whole was washed with water and 25 hydrochloric acid. The organic layer was dried, filtered and evaporated, yielding 7 parts (58%) of ethyl 3-(3-chlorophenyl)-3-hydroxy-1-piperidinecarboxylate as a residue (intermediate 50).

Example 14

A mixture of 11.8 parts of N-(2,3-dimethylphenyl)-1-(phenylmethyl)-3-piperidinamine and 120 parts of methanol was hydrogenated at normal pressure and at room temperature with 2 parts of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off over Hyflo and the filtrate was evaporated. The residue was purified by column chromatography over silica gel using 35 a mixture of trichloromethane and methanol (from 99:1 to 95:5 by

-25-

volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was converted into the ethanedioate salt in 2-propanol and 2-propanone. The salt was filtered off and dried, yielding 7 parts (79.5%) of N-(2,3-dimethylphenyl)-3-piperidinamine 5 ethanedioate (1:1); mp. 161.6°C (intermediate 51).

In a similar manner there were also prepared:

- ethyl 4-(1-piperazinyl)benzoate; mp. 102.6°C (intermediate 52);
- (4-piperidinyl) benzoate hydrochloride; mp. 236.8°C (intermediate 53);
- 10    N-phenyl-3-piperidinamine; mp. 79.8°C (intermediate 54);
- N-(3-methylphenyl)-3-piperidinamine as a residue (intermediate 55);
- 4-[(3-methylphenyl)amino]-4-piperidinecarboxamide as a residue (intermediate 56);
- 2-phenyl-1-(4-piperidinyl)ethanone hydrochloride; mp. 198.6°C; 15 (intermediate 57);
- 3-(3-methylphenyl)piperidine as a residue (intermediate 58);
- 3-(3-methylphenyl)-3-piperidinol hydrochloride (intermediate 59);
- cis-3-methyl-4-(3-methylphenyl)-4-piperidinol as a residue (intermediate 60);
- 20    3-(3-fluorophenyl)-3-piperidinol hydrochloride (intermediate 61);
- 3-(2,3-dimethylphenyl)-3-piperidinol hydrochloride hemihydrate; mp. 135.5°C (intermediate 62);
- 3-(2,3-dimethylphenyl)piperidine as a residue (intermediate 63);
- 3-(3-methylphenyl)-3-pyrrolidinol (intermediate 64);
- 25    3-(3-methoxyphenyl)-3-piperidinol hydrochloride as a residue (intermediate 65);
- 3-(3-fluorophenyl)-3-pyrrolidinol hydrochloride as a residue (intermediate 66); and
- 3-(3-methoxyphenyl)-3-pyrrolidinol hydrochloride as a residue 30 (intermediate 67).

Example 15

A mixture of 13.10 parts of ethyl 3-[(2,3-dimethylphenyl)amino]-1-pyrrolidinecarboxylate, 28 parts of potassium hydroxide and 240 parts of 2-propanol was stirred and refluxed for 6 hours. The reaction 35 mixture was evaporated. The residue was taken up in water. The product

-26-

was extracted with dichloromethane. The extract was dried, filtered and evaporated, yielding 6 parts (63%) of N-(2,3-dimethylphenyl)-3-pyrrolidinamine as a residue (intermediate 68).

In a similar manner there were also prepared:

5      (*E*)-N-methyl-N-(3-phenyl-2-propenyl)-4-piperidinamine dihydrochloride hemihydrate; mp. 240.2°C (intermediate 69);  
      N-[3-(trifluoromethyl)phenyl]-4-piperidinamine dihydrobromide;  
      mp. 253.2°C (intermediate 70);  
      N-(3-methylphenyl)-3-pyrrolidinamine ethanedioate(1:2); mp. 180°C  
10 (intermediate 71);  
      4-(2-thienyl)-4-piperidinol; mp. 145.9°C (intermediate 72);  
      4-(1-naphthalenyl)-4-piperidinol; mp. 185.1-187.8°C  
(intermediate 73);  
      3-[4-chloro-3-(trifluoromethyl)phenyl]-3-pyrrolidinol; mp.  
15 138.4-142.1°C (intermediate 74);  
      4-(2-naphthalenyl)-4-piperidinol (intermediate 75);  
      N-[3-(trifluoromethyl)phenyl]-3-pyrrolidinamine dihydrochloride  
(intermediate 76);  
      cis-4-(3-fluorophenyl)-3-methyl-4-piperidinol as a residue  
20 (intermediate 77);  
      cis-3-methyl-4-(2-thienyl)-4-piperidinol as a residue  
(intermediate 78);  
      3-(2-thienyl)-3-piperidinol (intermediate 79);  
      3-(3-chlorophenyl)-3-piperidinol hydrochloride (intermediate 80);  
25      4-(2,3-dimethylphenyl)-4-piperidinol (intermediate 81);  
      4-(3-chlorophenyl)-3-methyl-4-piperidinol as a residue  
(intermediate 82);  
      3-[4-chloro-3-(trifluoromethyl)phenyl]-3-piperidinol  
(intermediate 83); and  
30      4-(3-methoxyphenyl)-3-methyl-4-piperidinol as a residue  
(intermediate 84).

Example 16

A mixture of 3 parts of 3-(3-fluorophenyl)-3-piperidinol hydrochloride and 100 parts of a hydrochloric acid solution 6N was stirred and refluxed for 3 hours. The reaction mixture was evaporated.

-27-

The residue was taken up in water and ammonium hydroxide. The product was extracted with trichloromethane. The extract was washed with water, dried, filtered and evaporated, yielding 2.2 parts (96%) of 5-(3-fluorophenyl)-1,2,3,6-tetrahydropyridine as a residue.

5 (intermediate 85).

Following the same procedure and using equivalent amounts of the appropriate starting materials, there were also prepared:

4-[4-chloro-3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine hydrochloride (intermediate 86);

10 1,2,3,6-tetrahydro-4-(2-thienyl)pyridine hydrochloride

(intermediate 87);

1,2,3,6-tetrahydro-4-[3-(trifluoromethyl)phenyl]pyridine as a residue (intermediate 88);

1,2,3,6-tetrahydro-4-(1-naphthalenyl)pyridine hydrochloride;

15 mp. 277.5°C (intermediate 89);

1,2,3,6-tetrahydro-5-(3-methylphenyl)pyridine hydrochloride

(intermediate 90);

3,4-dihydro-3-(2-thienyl)-1H-pyrrole as a residue (intermediate 91);

and

20 3-(2-thienyl)pyrrolidine as a residue (intermediate 92).

Example 17

A mixture of 6.5 parts of 5-(3-fluorophenyl)-1,2,3,6-tetrahydro-1-(phenylmethyl)pyridine hydrochloride and 120 parts of methanol was hydrogenated at normal pressure and at 50°C with 1 part of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated, yielding 4.5 parts (100%) of 3-(3-fluorophenyl)-piperidine hydrochloride as a residue (intermediate 93).

In a similar manner there were also prepared:

30 4-(2-thienyl)piperidine hydrochloride (intermediate 94); and

3-(3-methylphenyl)pyrrolidine hydrochloride as a residue

(intermediate 95).

Example 18

A mixture of 21 parts of N-(3-methylphenyl)-1-(phenylmethyl)-35 4-piperidinamine dihydrochloride, 9 parts of poly(oxymethylene), 15

-28-

parts of potassium acetate, 2 parts of a solution of thiophene in methanol 4% and 200 parts of methanol was hydrogenated at normal pressure and at room temperature with 4 parts of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off over Hyflo and the filtrate was evaporated. From the residue, the free base was liberated with ammonium hydroxide and extracted with dichloromethane. The extract was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (99:1 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was converted into the hydrochloride salt in 2-propanol. The salt was filtered off and dried, yielding 2.4 parts (75%) of N-methyl-N-(3-methylphenyl)-1-(phenylmethyl)-4-piperidinamine dihydrochloride hemihydrate: mp. 201.3°C (intermediate 96).

15 A mixture of 9 parts of N-methyl-N-(3-methylphenyl)-1-(phenylmethyl)-4-piperidinamine dihydrochloride hemihydrate and 200 parts of methanol was hydrogenated at normal pressure and at room temperature with 2 parts of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off over Hyflo and the filtrate was evaporated. The residue was converted into the hydrochloride salt in 2-propanol. The salt was filtered off and dried, yielding 1.5 parts (60.9%) of N-methyl-N-(3-methylphenyl)-4-piperidinamine dihydrochloride monohydrate; mp. 209.1°C (intermediate 97).

25

B. Preparation of Final compounds

Example 19

A mixture of 47.6 parts of 1*H*-imidazole, 33.6 parts of sodium hydride dispersion 50% and 750 parts of N,N-dimethylformamide was stirred at room temperature for 15 minutes. The resulting solution was added to 106 parts of 3,6-dichloropyridazine in 750 parts of N,N-dimethylformamide and the whole was further stirred for 2 days at room temperature. The product was extracted with trichloromethane. The extract was dried, filtered and evaporated. The residue was crystallized from methanol. The product was filtered off, washed with

petroleumether and dried, yielding 48.5 parts of 3-chloro-6-(1H-imidazol-1-yl)pyridazine; mp. 182.9°C (compound 1).

Example 20

A mixture of 3 parts of 3,5-dimethylphenol, 1.25 parts of sodium 5 hydride dispersion 50% and 25 parts of N,N-dimethylformamide was stirred for 15 minutes. Then there was added a solution of 4.5 parts of 3-chloro-6-(1H-imidazol-1-yl)pyridazine in 25 parts of N,N-dimethyl-formamide and the whole was stirred over weekend at 50°C. The reaction mixture was poured onto water and the product was extracted with 10 trichloromethane. The extract was dried, filtered and evaporated. The residue was crystallized from 2-propanone, yielding 3.5 parts of 3-(3,5-dimethylphenoxy)-6-(1H-imidazol-1-yl)pyridazine; mp. 169.8°C (compound 2).

In a similar manner there were also prepared:

15 3-(1H-imidazol-1-yl)-6-(4-methylphenoxy)pyridazine; mp. 146.8°C (compound 3);

3-(1H-imidazol-1-yl)-6-(3-nitrophenoxy)pyridazine; mp. 171.5°C (compound 4); and

3-(4-chlorophenoxy)-6-(1H-imidazol-1-yl)-pyridazine; mp. 165.8°C 20 (compound 5).

Example 21

A mixture of 4.5 parts of 3-chloro-6-(1H-imidazol-1-yl)pyridazine, 3.2 parts of 4-bromophenol, 4.2 parts of sodium carbonate and 80 parts of 2-propanone was stirred and refluxed over weekend. The reaction 25 mixture was evaporated and the residue was taken up in water and 2.2'-oxybispropane. The layers were separated. The organic phase was dried, filtered and evapoated. The residue was crystallized from 2-propanol, yielding 3.5 parts of 3-(4-bromophenoxy)-6-(1H-imidazol-1-yl)pyridazine; mp. 168.4°C (compound 6).

30 Example 22

A mixture of 4.35 parts of 1-(4-fluorophenyl)-4-oxocyclohexane-carbonitrile, 3.3 parts of 1-(3-piperazinyl)pyridazine, 0.2 parts of 4-methylbenzenesulfonic acid and 360 parts of methylbenzene was stirred and refluxed overnight using a water separator. The reaction mixture 35 was cooled and evaporated, yielding 7.3 parts (100%) of 1-(4-fluoro-

-30-


phenyl)-4-[4-(3-pyridazinyl)-1-piperazinyl]-3-cyclohexenecarbonitrile as a residue (compound 7).

To a stirred mixture of 7.3 parts of 1-(4-fluorophenyl)-4-[4-(3-pyridazinyl)-1-piperazinyl]-3-cyclohexenecarbonitrile, 1 part of sodium methoxide solution 30% and 240 parts of methanol were added portionwise 0.8 parts of sodium borohydride. Upon completion, stirring was continued overnight at room temperature. The reaction mixture was poured onto ice water and the product was extracted with trichloromethane. The extract was dried, filtered and evaporated. The residue was crystallized from 2-propanol, yielding 4.5 parts (61.5%) of 1-(4-fluorophenyl)-4-[4-(3-pyridazinyl)-1-piperazinyl]cyclohexanecarbonitrile; mp. 188.7°C (compound 8).

Example 23

A mixture of 3.1 parts of 3,6-dichloropyridazine, 3 parts of 1-(2-fluorophenyl)piperazine, 3.2 parts of sodium carbonate, 0.1 parts of potassium iodide and 72 parts of N,N-dimethylformamide was stirred and heated over weekend at 60°C. The reaction mixture was poured into water. The precipitated product was filtered off and dissolved in trichloromethane. The organic layer was dried, filtered and evaporated. The residue was purified by filtration over silica gel using a mixture of trichloromethane and methanol (98:2 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from a mixture of 2-propanol and 2,2'-oxybispropane, yielding 4.5 parts (77%) of 3-chloro-6-[4-(2-fluorophenyl)-1-piperazinyl]pyridazine; mp. 148.0°C (compound 9).

Following the same procedure and using equivalent amounts of the appropriate starting materials, there were also prepared:



No.	R <sup>1</sup>	R <sup>2</sup>	A	mp. in °C
10	Cl	H	(CH <sub>2</sub> ) <sub>2</sub> -N-(2-C <sub>2</sub> H <sub>5</sub> -C <sub>6</sub> H <sub>4</sub> ) (CH <sub>2</sub> ) <sub>2</sub>	107.9
11		H	(CH <sub>2</sub> ) <sub>2</sub> -N-(3-CH <sub>3</sub> -C <sub>6</sub> H <sub>4</sub> ) (CH <sub>2</sub> ) <sub>2</sub>	177.7
12	Cl	H	(CH <sub>2</sub> ) <sub>2</sub> -N-(3-C <sub>2</sub> H <sub>5</sub> -C <sub>6</sub> H <sub>4</sub> ) (CH <sub>2</sub> ) <sub>2</sub>	119.8
13	Cl	H	(CH <sub>2</sub> ) <sub>2</sub> -N-(5-CH <sub>3</sub> -2-pyridinyl) (CH <sub>2</sub> ) <sub>2</sub>	226.2
14	Cl	CH <sub>3</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N-(3-CH <sub>3</sub> -C <sub>6</sub> H <sub>4</sub> ) (CH <sub>2</sub> ) <sub>2</sub>	152.7
15	Cl	H	(CH <sub>2</sub> ) <sub>2</sub> -N-[2,4,6-(CH <sub>3</sub> ) <sub>3</sub> -C <sub>6</sub> H <sub>2</sub> ] (CH <sub>2</sub> ) <sub>2</sub>	149.8
16	Cl	CH <sub>3</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N-(3-Cl-C <sub>6</sub> H <sub>4</sub> ) (CH <sub>2</sub> ) <sub>2</sub>	163.5
17	Cl	H	(CH <sub>2</sub> ) <sub>2</sub> -N-(2-Br-C <sub>6</sub> H <sub>4</sub> ) (CH <sub>2</sub> ) <sub>2</sub>	191.4
18	Cl	H	(CH <sub>2</sub> ) <sub>2</sub> -CH-NH-(3-CH <sub>3</sub> -C <sub>6</sub> H <sub>4</sub> ) (CH <sub>2</sub> ) <sub>2</sub>	156.8
19	Cl	H	(CH <sub>2</sub> ) <sub>2</sub> -N-(2,3-Cl <sub>2</sub> -C <sub>6</sub> H <sub>3</sub> ) (CH <sub>2</sub> ) <sub>2</sub>	160.6
20	Cl	CH <sub>3</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N-(3-CP <sub>3</sub> -C <sub>6</sub> H <sub>4</sub> ) (CH <sub>2</sub> ) <sub>2</sub>	176.6
21	Cl	H	(CH <sub>2</sub> ) <sub>2</sub> -CH-C <sub>6</sub> H <sub>5</sub> (CH <sub>2</sub> ) <sub>2</sub>	122.7

-32-

22	Cl	H	$(CH_2)_2 - CH - (3-CH_3 - C_6H_4)$ $\quad\quad\quad  $ $\quad\quad\quad (CH_2)_2$	107.5
23	Cl	H	$(CH_2)_2 - CH - (3-CF_3 - C_6H_4)$ $\quad\quad\quad  $ $\quad\quad\quad (CH_2)_2$	69.8

5

Example 24

A mixture of 2.7 parts of 3,6-difluoropyridazine, 4.6 parts of 1-[3-(trifluoromethyl)phenyl]piperazine, 3.2 parts of sodium carbonate and 90 parts of N,N-dimethylformamide was stirred overnight at 60°C.

10 The reaction mixture was poured into water. The product was filtered off, washed with water and crystallized from 2-propanol, yielding 3 parts (46%) of 3-fluoro-6-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]pyridazine; mp. 131.5°C (compound 24).

In a similar manner there were also prepared:

15 3-[4-(2,3-dimethylphenyl)-1-piperazinyl]-6-fluoropyridazine; mp. 144.1°C (compound 25);

3-fluoro-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine; mp. 128.1°C (compound 26) and

3-[3,6-dihydro-4-(3-methylphenyl)-1(2H)-pyridinyl]-6-fluoropyridazine;  
20 mp. 105.2°C (compound 27).


Example 25

A mixture of 4.5 parts of 3,6-dichloropyridazine, 5.2 parts of 1,2,3,6-tetrahydro-4-(3-methylphenyl)pyridine, 5.3 parts of sodium carbonate and 72 parts of N,N-dimethylformamide was stirred and heated 25 overnight at about 70°C. The reaction mixture was evaporated and water was added to the residue. The product was extracted with trichloromethane. The extract was dried, filtered and evaporated. The residue was purified by filtration over silica gel using a mixture of trichloromethane and methanol (98:2 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was 30 crystallized from 2-propanol. The product was filtered off and dried, yielding 2.1 parts (24%) of 3-chloro-6-[3,6-dihydro-4-(3-methylphenyl)-1(2H)-pyridinyl]pyridazine; mp. 122.2°C (compound 28).

-33-

Following the same procedure and using equivalent amounts of the appropriate starting materials, there were also prepared:

5



10	R¹	A	Salt or base	mp. in °C
29	Cl	$(\text{CH}_2)_2 \begin{matrix}   \\ -\text{N}-\left(4-\text{CH}_3\text{O}-\text{C}_6\text{H}_4\right) \\ (\text{CH}_2)_2 \end{matrix}$	base	183.3
30	Cl	$\text{CH}_2-\text{CH}(\text{CH}_3)-\begin{matrix}   \\ -\text{N}-\left(4-\text{CH}_3\text{O}-\text{C}_6\text{H}_4\right) \\ (\text{CH}_2)_2 \end{matrix}$	base	133.5
15				
31	Cl	$(\text{CH}_2)_2 \begin{matrix}   \\ -\text{N}-\left(2-\text{thiazolyl}\right) \\ (\text{CH}_2)_2 \end{matrix}$	base	221.9
32	Cl	$(\text{CH}_2)_2 \begin{matrix}   \\ -\text{N}-\left(3-\text{Cl}-\text{C}_6\text{H}_4\right) \\ (\text{CH}_2)_2 \end{matrix}$	base	146.6
20				
33	Cl	$(\text{CH}_2)_2 \begin{matrix}   \\ -\text{N}-\text{C}_6\text{H}_5 \\ (\text{CH}_2)_2 \end{matrix}$	base	172.0
34	Cl	$(\text{CH}_2)_2 \begin{matrix}   \\ -\text{N}-\left(2-\text{CH}_3\text{O}-\text{C}_6\text{H}_4\right) \\ (\text{CH}_2)_2 \end{matrix}$	base	144.5
25				
35	Cl	$(\text{CH}_2)_2 \begin{matrix}   \\ -\text{N}-\left(4-\text{CH}_3-\text{C}_6\text{H}_4\right) \\ (\text{CH}_2)_2 \end{matrix}$	base	188.6
36	Cl	$(\text{CH}_2)_2 \begin{matrix}   \\ -\text{N}-\left[3,4-\left(\text{CH}_3\right)_2-\text{C}_6\text{H}_3\right] \\ (\text{CH}_2)_2 \end{matrix}$	base	162.6
30				
37	Cl	$(\text{CH}_2)_2 \begin{matrix}   \\ -\text{N}-\left(2-\text{pyrimidinyl}\right) \\ (\text{CH}_2)_2 \end{matrix}$	base	207.7
38	Cl	$(\text{CH}_2)_2 \begin{matrix}   \\ -\text{N}-\left[2,3-\left(\text{CH}_3\right)_2-\text{C}_6\text{H}_3\right] \\ (\text{CH}_2)_2 \end{matrix}$	base	164.6
39	Cl	$(\text{CH}_2)_2 \begin{matrix}   \\ -\text{N}-\left(3-\text{CH}_3-\text{C}_6\text{H}_4\right) \\ (\text{CH}_2)_2 \end{matrix}$	base	140.1
40	Cl	$\text{CH}_2-\text{CH}(\text{CH}_3)-\begin{matrix}   \\ -\text{N}-\left(2-\text{Cl}-\text{C}_6\text{H}_4\right) \\ (\text{CH}_2)_2 \end{matrix}$	base	118.2
35				

-34-

41	C1	$(\text{CH}_2)_2-\text{N}-(4-\text{C}_2\text{H}_5\text{OC(O)-C}_6\text{H}_4)$ $(\text{CH}_2)_2$	base	200.6
42	C1	$(\text{CH}_2)_2-\text{N}-(2,4-(\text{CH}_3)_2-\text{C}_6\text{H}_3)$ $(\text{CH}_2)_2$	base	155.8
5	43	$\text{CH}_2-\text{CH}(\text{CH}_3)-\text{N}-(4-\text{CH}_3-\text{C}_6\text{H}_4)$ $(\text{CH}_2)_2$	base	124.4
10	44	$(\text{CH}_2)_2-\text{N}-(2-\text{CH}_3\text{O},5-\text{CF}_3-\text{C}_6\text{H}_3)$ $(\text{CH}_2)_2$	base	160.0
15	45	$(\text{CH}_2)_2-\text{N}-\text{CH}(\text{C}_6\text{H}_5)_2$ $(\text{CH}_2)_2$	base	156.4
20	46	$\text{CH}_2-\text{CH}(\text{CH}_3)-\text{N}-(3-\text{CH}_3-\text{C}_6\text{H}_4)$ $(\text{CH}_2)_2$	base	114.8
25	47	$(\text{CH}_2)_2-\text{N}-(3-\text{F-C}_6\text{H}_4)$ $(\text{CH}_2)_2$	base	153.1
30	48	$(\text{CH}_2)_2-\text{N}-(3-\text{CN-2-pyridinyl})$ $(\text{CH}_2)_2$	base	177.3
	49	$(\text{CH}_2)_2-\text{N}-\text{C}_6\text{H}_4-\text{C(O)-(4-Cl-C}_6\text{H}_4)$ $(\text{CH}_2)_2$	base	262.5
	50	$\text{CH}_2-\text{CH}(\text{CH}_3)-\text{N}-(4-\text{Cl-C}_6\text{H}_4)$ $(\text{CH}_2)_2$	base	161.3
	51	$(\text{CH}_2)_2-\text{N}-(3,4-(\text{CH}_3\text{O})_2-\text{C}_6\text{H}_3)$ $(\text{CH}_2)_2$	base	149.5
	52	$\text{CH}_2-\text{CH}(\text{CH}_3)-\text{N}-\text{C}_6\text{H}_5$ $(\text{CH}_2)_2$	base	145.9
	53	$(\text{CH}_2)_2-\text{N}-(4-\text{OH-C}_6\text{H}_4)$ $(\text{CH}_2)_2$	base	203.5
	54	$(\text{CH}_2)_2-\text{CH-NH-C}_6\text{H}_5$ $(\text{CH}_2)_2$	base	149.6
	55	$(\text{CH}_2)_2-\text{N}-(3,5-\text{Cl}_2-\text{C}_6\text{H}_3)$ $(\text{CH}_2)_2$	base	167.2
	56	$(\text{CH}_2)_2-\text{N}-(3,5-(\text{CH}_3)_2-\text{C}_6\text{H}_3)$ $(\text{CH}_2)_2$	base	164.7

-35-

57	C1	$\text{CH}_2\text{--}\underset{\substack{  \\ (\text{CH}_2)_3}}{\text{CH--NH--}}[\text{2},\text{3}-\text{(CH}_3)_2\text{--C}_6\text{H}_3]$	HCl	218.0	
58	C1	$\text{CH}_2\text{--}\underset{\substack{  \\ (\text{CH}_2)_2}}{\text{CH--NH--}}(\text{3--CH}_3\text{--C}_6\text{H}_4)$	base	161.9	
5	59	C1	$\text{CH}_2\text{--}\underset{\substack{  \\ (\text{CH}_2)_3}}{\text{CH--NH--C}_6\text{H}_5}$	HCl	142.2
60	C1	$(\text{CH}_2)_3\text{--}\underset{\substack{  \\ (\text{CH}_2)_2}}{\text{N--}}(\text{3--Cl--C}_6\text{H}_4)$	base	123.0	
10	61	C1	$\text{CH}_2\text{--}\underset{\substack{  \\ (\text{CH}_2)_3}}{\text{CH--NH--}}(\text{3--CH}_3\text{--C}_6\text{H}_4)$	HCl	176.5
62	C1	$(\text{CH}_2)_2\text{--}\underset{\substack{  \\ (\text{CH}_2)_2}}{\text{N--}}(\text{2},\text{4--Cl--C}_6\text{H}_3)$	base	185.2	
15	63	C1	$(\text{CH}_2)_3\text{--}\underset{\substack{  \\ (\text{CH}_2)_2}}{\text{N--}}[\text{2},\text{3}-\text{(CH}_3)_2\text{--C}_6\text{H}_3]$	base	118.8
64	C1	$(\text{CH}_2)_3\text{--}\underset{\substack{  \\ (\text{CH}_2)_2}}{\text{N--}}(\text{3},\text{5--Cl--C}_6\text{H}_3)$	base	174.9	
20	65	C1	$\text{C}_6\text{H}_5\text{--}(\text{CH}_2)_2\text{--}\underset{\substack{  \\ (\text{CH}_2)_2}}{\text{C--C(O)--NH--C}_6\text{H}_5}$	base	224.4
25	66	C1	$(\text{CH}_2)_2\text{--}\underset{\substack{  \\ (\text{CH}_2)_2}}{\text{CH--N(CH}_3\text{)}(\text{3--CH}_3\text{--C}_6\text{H}_4)}$	base	136.5
67	C1	$(\text{CH}_2)_2\text{--}\underset{\substack{  \\ (\text{CH}_2)_2}}{\text{C--CH}_2\text{--}}(\text{4--Cl--C}_6\text{H}_4)$	base	172.9	
30	68	C1	$(\text{CH}_2)_2\text{--}\underset{\substack{  \\ (\text{CH}_2)_3}}{\text{C--C(OCH}_3\text{)--C}_6\text{H}_5}$	base	147.6

-36-

69	c1	$\begin{array}{c} \text{OH} \\   \\ (\text{CH}_2)_2-\text{C}-\text{(3-CF}_3-\text{C}_6\text{H}_4) \\   \\ (\text{CH}_2)_2 \end{array}$	HCl	194.5	
5	70	c1	$\begin{array}{c} \text{CH}_2-\text{NH}-\text{C(O)-CH}_3 \\   \\ (\text{CH}_2)_2-\text{C}-\text{(4-CH}_3-\text{C}_6\text{H}_4) \\   \\ (\text{CH}_2)_2 \end{array}$	base	221.8
10	71	c1	$\begin{array}{c} \text{CH}_3 \\   \\ (\text{CH}_2)_2-\text{CH-N-CH}_2-\text{CH=CH-C}_6\text{H}_5 \\   \\ (\text{CH}_2)_2 \end{array}$	base	95.2
15	72	c1	$\begin{array}{c} \text{OH} \\   \\ (\text{CH}_2)_2-\text{C}-\text{(3-Br-4-Cl-C}_6\text{H}_3) \\   \\ (\text{CH}_2)_2 \end{array}$	base	199.6
20	73	c1	$\begin{array}{c} \text{CH}_2-\text{CH-NH-C}_6\text{H}_5 \\   \\ (\text{CH}_2)_2 \end{array}$	base	167.9
25	74	c1	$\begin{array}{c} (\text{CH}_2)_2-\text{CH-O-C(O)-C}_6\text{H}_5 \\   \\ (\text{CH}_2)_2 \end{array}$	base	120.9
30	75	c1	$\begin{array}{c} \text{CH}_3 \\   \\ (\text{CH}_2)_2-\text{C-CH}_2-\text{CH}_3 \\   \\ (\text{CH}_2)_2 \end{array}$	base	80.4
35	76	c1	$\begin{array}{c} \text{C(O)-OCH}_3 \\   \\ (\text{CH}_2)_2-\text{C-NH-(3-CF}_3-\text{C}_6\text{H}_4) \\   \\ (\text{CH}_2)_2 \end{array}$	base	119.0
	77	c1	$\begin{array}{c} \text{CH}_2-\text{CH=CH-C-(3-CF}_3-\text{C}_6\text{H}_4 \\   \\ (\text{CH}_2)_2 \end{array}$	base	120.8
	78	c1	$\begin{array}{c} \text{C}_6\text{H}_5 \\   \\ (\text{CH}_2)_2-\text{C-C}_6\text{H}_5 \\   \\ (\text{CH}_2)_2 \end{array}$	base	178.7
	79	c1	$\begin{array}{c} \text{OH} \\   \\ (\text{CH}_2)_2-\text{C}-\text{(3-CH}_3-\text{C}_6\text{H}_4) \\   \\ (\text{CH}_2)_2 \end{array}$	base	140.4

-37-

80	C1	$\text{CH}_2-\underset{(\text{CH}_2)_2}{\overset{ }{\text{CH}}}-\text{NH}-[(2,3-\text{CH}_3)_2\text{C}_6\text{H}_3]$	base	163.2
81	C1	$(\text{CH}_2)_2-\underset{(\text{CH}_2)_2}{\overset{ }{\text{N}}}- (2-\text{CH}_3-\text{C}_6\text{H}_4)$	base	148.0
82	C1	$(\text{CH}_2)_2-\underset{(\text{CH}_2)_2}{\overset{ }{\text{C}}}- (3-\text{CH}_3-\text{C}_6\text{H}_4)$	base	237.8
83	C1	$(\text{CH}_2)_2-\underset{(\text{CH}_2)_2}{\overset{ }{\text{CH}}}-\text{CO}- (3-\text{CP}_3-\text{C}_6\text{H}_4)$	base	126.0
84	C1	$(\text{CH}_2)_3-\underset{(\text{CH}_2)_2}{\overset{ }{\text{N}}}- (3-\text{CH}_3\text{O}-\text{C}_6\text{H}_4)$	HCl	173.8
85	C1	$(\text{CH}_2)_2-\underset{(\text{CH}_2)_2}{\overset{ }{\text{CH}}}- (4-\text{CH}_3-\text{C}_6\text{H}_4)$	base	127.9
86*	C1	$\text{CH}_2-\text{CH}(\text{CH}_3)-\underset{(\text{CH}_2)_2}{\overset{ }{\text{C}}}- (3-\text{CP}_3-\text{C}_6\text{H}_4)$	base	163.8
87	C1	$(\text{CH}_2)_2-\underset{(\text{CH}_2)_2}{\overset{ }{\text{C}}}- (2-\text{thienyl})$	base	162.7
88	C1	$\text{CH}_2-\underset{(\text{CH}_2)_2}{\overset{ }{\text{CH}}}-\text{NH}- (3-\text{CP}_3-\text{C}_6\text{H}_4)$	base	152.0
89	C1	$(\text{CH}_2)_2-\underset{(\text{CH}_2)_2}{\overset{ }{\text{N}}}- (2-\text{quinolinyl})$	base	207.7
90	C1	$(\text{CH}_2)_2-\underset{\text{CH}_2-\text{CH}}{\overset{ }{\text{C}}}- (2-\text{thienyl})$	base	156.4

\* cis form

-38-

91	C1	$\text{CH}_2-\text{CH}-(4-\text{Cl}-\text{C}_6\text{H}_4)$ $(\text{CH}_2)_3$	base	118.9
5	92	C1	$(\text{CH}_2)_2-\overset{\text{OH}}{\underset{(\text{CH}_2)_2}{\text{C}}}-(3-\text{Cl}-\text{C}_6\text{H}_4)$	base 206.0
93	C1	$(\text{CH}_2)_2-\overset{\text{OH}}{\underset{(\text{CH}_2)_2}{\text{CH}}}-\text{O}-(4-\text{F}-\text{C}_6\text{H}_4)$	base 147.0	
10	94	C1	$(\text{CH}_2)_2-\overset{\text{CH}_2-\text{CH}}{\underset{  }{\text{C}}}-\text{(4-Cl, 3-CF}_3\text{-C}_6\text{H}_3\text{)}$	base 137.5
95	C1	$(\text{CH}_2)_2-\overset{\text{OH}}{\underset{(\text{CH}_2)_2}{\text{C}}}-(3-\text{CH}_3\text{O}-\text{C}_6\text{H}_4)$	base 134.7	
15	96	C1	$(\text{CH}_2)_2-\overset{\text{CH}_2}{\underset{(\text{CH}_2)_2}{\text{N}}}-\text{CH}_2-(2-\text{CH}_3-\text{C}_6\text{H}_4)$	base 134.7
20	97*	C1	$\text{CH}_2-\text{CH}(\text{CH}_3)-\overset{\text{OH}}{\underset{(\text{CH}_2)_2}{\text{C}}}-(3-\text{CH}_3-\text{C}_6\text{H}_4)$	base 154.0
98	C1	$(\text{CH}_2)_2-\overset{\text{CH}_2}{\underset{(\text{CH}_2)_2}{\text{CH}}}-\text{NH}-(3-\text{Cl}-\text{C}_6\text{H}_4)$	base 153.3	
25	99*	C1	$\text{CH}_2-\text{CH}(\text{CH}_3)-\overset{\text{OH}}{\underset{(\text{CH}_2)_2}{\text{C}}}-(3-\text{F}-\text{C}_6\text{H}_4)$	base 160.5
100*	C1	$\text{CH}_2-\text{CH}(\text{CH}_3)-\overset{\text{OH}}{\underset{(\text{CH}_2)_2}{\text{C}}}-(2-\text{thienyl})$	base 148.1	
30	101	C1	$(\text{CH}_2)_2-\overset{\text{CH}_2}{\underset{(\text{CH}_2)_2}{\text{CH}}}-\text{(1H-indol-3-yl)}$	base 182.7

\* cis form

-39-

102	C1	$\begin{array}{c} \text{OH} \\   \\ (\text{CH}_2)_2-\text{C}-\text{(3-F-C}_6\text{H}_4) \\   \\ (\text{CH}_2)_2 \end{array}$	base	156.8
5	103	C1 $\begin{array}{c} \text{OH} \\   \\ (\text{CH}_2)_2-\text{C}-\text{[2,3-(CH}_3)_2-\text{C}_6\text{H}_3] \\   \\ (\text{CH}_2)_2 \end{array}$	base	175.0
10	104	C1 $\begin{array}{c} \text{OH} \\   \\ (\text{CH}_2)_2-\text{C}-\text{(1-naphthalenyl)} \\   \\ (\text{CH}_2)_2 \end{array}$	base	201.8
15	105	C1 $\begin{array}{c} \text{OH} \\   \\ \text{CH}_2-\text{CH(CH}_3)-\text{C}-\text{(3-Cl-C}_6\text{H}_4) \\   \\ (\text{CH}_2)_2 \end{array}$	HCl	200
20	106	C1 $\begin{array}{c} \text{OH} \\   \\ (\text{CH}_2)_2-\text{C}-\text{(4-Cl, 3-CP}_3-\text{C}_6\text{H}_3) \\   \\ (\text{CH}_2)_2 \end{array}$	base	208.4
25	107	C1 $\begin{array}{c} \text{OH} \\   \\ (\text{CH}_2)_2-\text{C}-\text{(4-Br-C}_6\text{H}_4) \\   \\ (\text{CH}_2)_2 \end{array}$	base	169.4
30	108	C1 $\begin{array}{c} \text{OH} \\   \\ (\text{CH}_2)_2-\text{C}-\text{(CH}_2)_3-\text{C}_6\text{H}_5 \\   \\ (\text{CH}_2)_2 \end{array}$	base	105.1
35	109	C1 $\begin{array}{c} \text{OH} \\   \\ (\text{CH}_2)_2-\text{C}-\text{(4-Cl-C}_6\text{H}_4) \\   \\ (\text{CH}_2)_2 \end{array}$	base	161.5
	110	C1 $\begin{array}{c} \text{OH} \\   \\ (\text{CH}_2)_2-\text{C}-\text{(4-CH}_3-\text{C}_6\text{H}_4) \\   \\ (\text{CH}_2)_2 \end{array}$	base	123.1
	111	C1 $\begin{array}{c} \text{OH} \\   \\ (\text{CH}_2)_2-\text{C}-\text{(4-F-C}_6\text{H}_4) \\   \\ (\text{CH}_2)_2 \end{array}$	base	156.6

-40-

112	C1	$(\text{CH}_2)_2-\text{C}(\text{CH}_2)_2-\text{C}-(1\text{-naphthalenyl})$	base	138.4
113	$\text{CH}_3\text{O}-\text{C}$	$(\text{CH}_2)_2-\text{N}(\text{CH}_2)_2-\text{C}-(3-\text{CH}_3-\text{C}_6\text{H}_4)$	base	185.5
114	C1	$(\text{CH}_2)_2-\text{C}(\text{CH}_2)_2-\text{C}(\text{OH})-\text{[4-CH(CH}_3)_2-\text{C}_6\text{H}_4]$	base	136.5
115	C1	$(\text{CH}_2)_2-\text{C}(\text{CH}_2)_2-\text{C}(\text{OH})-\text{C}_6\text{H}_5$	base	106.2
116	C1	$(\text{CH}_2)_2-\text{C}(\text{CH}_2)_2-\text{C}(\text{OH})-\text{C}_6\text{H}_5$	base	147.3
117	C1	$(\text{CH}_2)_2-\text{C}(\text{CH}_2)_2-\text{C}-(2\text{-naphthalenyl})$	base	196.1
118	C1	$(\text{CH}_2)_2-\text{N}(\text{CH}_2)_2-\text{C}-(4-\text{NO}_2-\text{C}_6\text{H}_4)$	HCl.1/2H <sub>2</sub> O	266.7
119	C1	$(\text{CH}_2)_2-\text{C}(\text{CH}_2)_2-\text{C}-(4-\text{CH}_3\text{O}-\text{C}_6\text{H}_4)$	base	173.7
120	NC	$(\text{CH}_2)_2-\text{N}(\text{CH}_2)_2-\text{C}-(3-\text{CH}_3-\text{C}_6\text{H}_4)$	base	179.8
121	C1	$(\text{CH}_2)_2-\text{C}(\text{CH}_2)_2-\text{C}-(4-\text{Cl-C}_6\text{H}_4)$	base	204.5
122	C1	$\text{CH}_2-\text{CH}(\text{CH}_3)-\text{C}(\text{CH}_2)_2-\text{C}-(3-\text{OCH}_3-\text{C}_6\text{H}_4)$	HCl	196.1
123	C1	$(\text{CH}_2)_2-\text{C}(\text{CH}_2)_2-\text{C}(\text{OH})-\text{CH}_3$	base	125.1

	124	<chem>CC(=O)C</chem>	$(\text{CH}_2)_2 - \underset{\text{CH}_2 - \text{CH}}{\overset{\parallel}{\text{C}}} - (\text{3-CH}_3 - \text{C}_6\text{H}_4)$	base	159.6
5	125		$(\text{CH}_2)_2 - \underset{\text{CH}_2 - \text{CH}}{\overset{\parallel}{\text{C}}} - (\text{3-CH}_3 - \text{C}_6\text{H}_4)$	base	164.8
10	126	<chem>Cl</chem>	$(\text{CH}_2)_2 - \underset{(\text{CH}_2)_2}{\text{N}} - (\text{l-naphthalenyl})$	base	156.6
127	127	<chem>CC(=O)C</chem>	$(\text{CH}_2)_2 - \underset{(\text{CH}_2)_2}{\overset{\mid}{\text{C}}} - (\text{3-CH}_3 - \text{C}_6\text{H}_4)$	base	-
15	128	<chem>Cl</chem>	$\text{CH}_2 - \underset{\text{CH}_2 - \text{CH}}{\overset{\parallel}{\text{C}}} - (\text{2-thienyl})$	base	210.7
129	129	<chem>I</chem>	$(\text{CH}_2)_2 - \underset{\text{CH}_2 - \text{CH}}{\overset{\parallel}{\text{C}}} - (\text{3-CH}_3 - \text{C}_6\text{H}_4)$	base	145.4
20	130	<chem>C#N</chem>	$(\text{CH}_2)_2 - \underset{\text{CH}_2 - \text{CH}}{\overset{\parallel}{\text{C}}} - (\text{3-CH}_3 - \text{C}_6\text{H}_4)$	base	138.0
131	131	<chem>Cl</chem>	$(\text{CH}_2)_2 - \underset{(\text{CH}_2)_2}{\overset{\mid}{\text{C}}} - (\text{2-pyridinyl})$	base	-
25	132	<chem>Cl</chem>	$(\text{CH}_2)_2 - \underset{\text{CH}_2 - \text{CH}}{\overset{\parallel}{\text{C}}} - (\text{2-pyridinyl})$	base	-
133	133	<chem>Cl</chem>	$(\text{CH}_2)_2 - \underset{\text{CH}_2 - \text{CH}}{\overset{\parallel}{\text{C}}} - \text{CH}_3$	base	-
30	134	<chem>Cl</chem>	$(\text{CH}_2)_2 - \underset{\text{CH}_2 - \text{CH}}{\overset{\parallel}{\text{C}}} - (\text{CH}_2)_3 - \text{CH}_3$	base	-

35 In a similar manner there was also prepared:  
 ethyl 4-(6-chloro-5-methyl-3-pyridazinyl)-1-piperazinecarboxylate; mp.  
 132.2°C (compound 135).

Example 26

A mixture of 5 parts of 1-(3-methylphenyl)piperazine dihydrochloride, 10.6 parts of sodium carbonate and 180 parts of N,N-dimethylformamide was stirred for 1 hour at 65°C. Then there were added 7.2 parts of 3,6-dibromopyridazine and the whole was stirred overnight at about 65°C. The reaction mixture was poured into ice water. The product was filtered off and dissolved in dichloromethane. The solution was washed twice with water, dried, filtered and evaporated. The residue was crystallized from ethanol. The product was filtered off and dried, yielding 4.1 parts (61.5%) of 3-bromo-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine; mp. 145.7°C (compound 136).

In a similar manner there were also prepared:

3-bromo-6-[4-(2,3-dimethylphenyl)-1-piperazinyl]pyridazine;  
mp. 166.7°C (compound 137);

15 3-bromo-6-[4-(3-chlorophenyl)-1-piperazinyl]pyridazine;  
mp. 158.7°C (compound 138);

3-bromo-6-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]pyridazine;  
mp. 154.3°C (compound 139);

3-bromo-6-[4-(2-methoxyphenyl)-1-piperazinyl]pyridazine;  
20 mp. 164.8°C (compound 140);

3-bromo-6-[4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]pyridazine  
monohydrochloride; mp. 222.5°C (compound 141);

3-bromo-6-[3,6-dihydro-4-[3-(trifluoromethyl)phenyl]-1(2H)-  
pyridinyl]-pyridazine; mp. 130.6°C (compound 142);

25 1-(6-bromo-3-pyridazinyl)-4-(3-chlorophenyl)-hexahydro-1H-1,4-  
diazepine; mp. 148.8°C (compound 143);

3-bromo-6-[4-(3-bromophenyl)-1-piperazinyl]pyridazine; mp. 179.8°C  
(compound 144); and

3-bromo-6-[3,6-dihydro-4-(3-methylphenyl)-1(2H)-pyridinyl]-  
30 pyridazine; mp. 127.1°C (compound 145);

Example 27

A mixture of 4.5 parts of 3,6-dichloropyridazine, 4.9 parts of N-[3-(trifluoromethyl)phenyl]-3-piperidinamine, 6.4 parts of sodium carbonate and 180 parts of N,N-dimethylformamide was stirred overnight at about 65°C. The reaction mixture was poured into ice water and the

-43-


product was extracted with dichloromethane. The extract was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (99:1 by volume) as eluent. The pure fractions were collected and the 5 eluent was evaporated. The residue was crystallized from 2-propanol. The product was filtered off (the filtrate was set aside) and dried, yielding 1.2 parts (16.8%) of 1-(6-chloro-3-pyridazinyl)-N-[3-(trifluoromethyl)phenyl]-3-piperidinamine; mp. 92.6°C (compound 146). The filtrate, which was set aside, was converted into the hydrochloride 10 salt in 2-propanol. The salt was filtered off and dried, yielding 2.6 parts (32.9%) of 1-(6-chloro-3-pyridazinyl)-N-[3-(trifluoromethyl)-phenyl]-3-piperidinamine monohydrochloride; mp. 173.5°C (compound 147).

Example 28

A mixture of 3 parts of 3,6-dichloropyridazine, 6.1 parts of 15 N-[3-(trifluoromethyl)phenyl]-4-piperidinamine dihydrobromide, 6.4 parts of sodium carbonate and 180 parts of N,N-dimethylacetamide was stirred for 24 hours at 60°C. After cooling to room temperature, the reaction mixture was poured onto water. The product was extracted with methylbenzene. The extract was washed with water, dried, filtered and 20 evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (97:3 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from 2,2'-oxybispropane. The product was filtered off and dried, yielding 2.5 parts (47%) of 25 1-(6-chloro-3-pyridazinyl)-N-[3-(trifluoromethyl)phenyl]-4-piperidinamine; mp. 117.9°C (compound 148).

Following the same procedure and using equivalent amounts of the appropriate starting materials, there were also prepared:

5



No.	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	A	Salt or base	mp. in °C
10	149	Cl	H	(CH <sub>2</sub> ) <sub>2</sub> -N-(4-Cl-C <sub>6</sub> H <sub>4</sub> )  (CH <sub>2</sub> ) <sub>2</sub>	base	209.7
15	150	Cl	H	(CH <sub>2</sub> ) <sub>2</sub> -N-(2-Cl-C <sub>6</sub> H <sub>4</sub> )  (CH <sub>2</sub> ) <sub>2</sub>	base	184.7
20	151	Cl	H	(CH <sub>2</sub> ) <sub>2</sub> -N-(3-CH <sub>3</sub> O-C <sub>6</sub> H <sub>4</sub> )  (CH <sub>2</sub> ) <sub>2</sub>	base	127.0
25	152	Cl	H	(CH <sub>2</sub> ) <sub>2</sub> -N-(4-F-C <sub>6</sub> H <sub>4</sub> )  (CH <sub>2</sub> ) <sub>2</sub>	base	197.4
30	153	Cl	H	(CH <sub>2</sub> ) <sub>2</sub> -N-(3,4-Cl <sub>2</sub> -C <sub>6</sub> H <sub>3</sub> )  (CH <sub>2</sub> ) <sub>2</sub>	base	160.5
35	154	Cl	H	(CH <sub>2</sub> ) <sub>2</sub> -N-[2,6-(CH <sub>3</sub> ) <sub>2</sub> -C <sub>6</sub> H <sub>3</sub> ]  (CH <sub>2</sub> ) <sub>2</sub>	base	124.4
	155	Cl	-CH=CH-CH=CH-	(CH <sub>2</sub> ) <sub>2</sub> -N-[2,3-(CH <sub>3</sub> ) <sub>2</sub> -C <sub>6</sub> H <sub>3</sub> ]  (CH <sub>2</sub> ) <sub>2</sub>	base	209.2
	156	Cl	-CH=CH-CH=CH-	(CH <sub>2</sub> ) <sub>2</sub> -N-(2-CH <sub>3</sub> O-C <sub>6</sub> H <sub>4</sub> )  (CH <sub>2</sub> ) <sub>2</sub>	base	178.6
	157	Cl	-CH=CH-CH=CH-	(CH <sub>2</sub> ) <sub>2</sub> -N-C <sub>6</sub> H <sub>5</sub>  (CH <sub>2</sub> ) <sub>2</sub>	base	170.2

-45-

158	C1	$-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$	$(\text{CH}_2)_2-\overset{\text{N}}{\underset{(\text{CH}_2)_2}{\text{C}}}-(3-\text{CP}_3-\text{C}_6\text{H}_4)$	base	167.2	
5	159	C1	$-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$	$(\text{CH}_2)_2-\overset{\text{N}}{\underset{(\text{CH}_2)_2}{\text{C}}}-(3-\text{Cl}-\text{C}_6\text{H}_4)$	base	167.0
10	160	C1	$-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$	$(\text{CH}_2)_2-\overset{\text{N}}{\underset{(\text{CH}_2)_2}{\text{C}}}-(3-\text{CH}_3-\text{C}_6\text{H}_4)$	base	135.6
15	161	C1	$-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$	$(\text{CH}_2)_2-\overset{\text{N}}{\underset{(\text{CH}_2)_2}{\text{C}}}-(3,5-\text{Cl}_2-\text{C}_6\text{H}_3)$	base	225.6
20	162	C1	H H	$(\text{CH}_2)_2-\overset{\text{OH}}{\underset{(\text{CH}_2)_2}{\text{C}}}-(3,4-\text{Cl}_2-\text{C}_6\text{H}_3)$	base	196.3
25	163	C1	H H	$(\text{CH}_2)_2-\overset{\text{C(O)O-CH}_2\text{CH}_3}{\underset{(\text{CH}_2)_2}{\text{C}}}-(3-\text{Cl}-\text{C}_6\text{H}_4)$	base	155.5
30	164	C1	H H	$(\text{CH}_2)_2-\overset{\text{C(O)-NH}_2}{\underset{(\text{CH}_2)_2}{\text{C}}}-\text{NH}-(3-\text{CH}_3-\text{C}_6\text{H}_4)$	base	195.1
165	C1	H H	$(\text{CH}_2)_2-\overset{\text{(3-Br-C}_6\text{H}_4)}{\underset{(\text{CH}_2)_2}{\text{N}}}$	base	157.1	
166	C1	H H	$(\text{CH}_2)_2-\overset{\text{O-(CH}_2)_3-(1-\text{piperidinyl})}{\underset{(\text{CH}_2)_2}{\text{C}}}-\text{C}_6\text{H}_5$	base	137.1	
167	C1	H H	$(\text{CH}_2)_2-\overset{(\text{CH}_2)_2-\text{CH}_3}{\underset{(\text{CH}_2)_2}{\text{C}}}-\text{C}_6\text{H}_5$	base	136.8	

-46-

168	C1	H	H	$\text{CH}_2-\overset{\text{CH}_2}{\underset{(\text{CH}_2)_2}{\text{CH}}}-\text{(3-CP}_3-\text{C}_6\text{H}_4)$	$1/2 (\text{COOH})_2$	155.2	
5	169	C1	$-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$	$(\text{CH}_2)_2-\overset{\text{CH}_2}{\underset{(\text{CH}_2)_2}{\text{N}}}-\text{(2,3-Cl}_2-\text{C}_6\text{H}_3)$	base	218.5	
10	170	C1	H	H	$(\text{CH}_2)_3-\overset{\text{CH}_2}{\underset{(\text{CH}_2)_2}{\text{N}}}-\text{C}_6\text{H}_5$	base	132.7
15	171	C1	H	H	$(\text{CH}_2)_2-\overset{\text{CH}_2}{\underset{(\text{CH}_2)_2}{\text{CH}}}-\text{CO-CH}_2-\text{C}_6\text{H}_5$	base	130.2
20	172	C1	H	H	$(\text{CH}_2)_3-\overset{\text{CH}_2}{\underset{\text{CH}_2}{\text{CH}}}-\text{(3-CP}_3-\text{C}_6\text{H}_4)$	base	121.7
25	173	C1	H	H	$(\text{CH}_2)_2-\overset{\text{CH}_2}{\underset{(\text{CH}_2)_2}{\text{CH}}}-\text{CH}_2-\text{CO-}(3-\text{F-C}_6\text{H}_4)$	base	156.2
30	174	C1	H	H	$(\text{CH}_2)_2-\overset{\text{OH}}{\underset{\text{CH}_2}{\text{C}}}-\text{(3-Cl-C}_6\text{H}_4)$	base	170.4
35	175	C1	H	H	$(\text{CH}_2)_3-\overset{\text{CH}_2}{\underset{(\text{CH}_2)_2}{\text{N}}}-\text{(3-CP}_3-\text{C}_6\text{H}_4)$	base	144.7
	176	C1	H	H	$\text{CH}_2-\overset{\text{OH}}{\underset{(\text{CH}_2)_3}{\text{C}}}-\text{C}_6\text{H}_5$	base	138.0
	177	C1	H	H	$\text{CH}_2-\overset{\text{OH}}{\underset{(\text{CH}_2)_3}{\text{C}}}-\text{(3-CP}_3-\text{C}_6\text{H}_4)$	base	95.0
	178	C1	H	H	$(\text{CH}_2)_3-\overset{\text{H}}{\underset{\text{CH}_2}{\text{C}}}-\text{C}_6\text{H}_5$	base	107.5
	179	C1	H	H	$(\text{CH}_2)_3-\overset{\text{H}}{\underset{\text{CH}_2}{\text{C}}}-\text{(3-CH}_3-\text{C}_6\text{H}_4)$	HBr $1/2 \text{CH}_3-\text{CHOH-CH}_3$	193.0

-47-

180	Cl	H	H	$(\text{CH}_2)_3 - \underset{\text{CH}_2}{\underset{ }{\text{C}}}(\text{OH}) - (\text{3-CH}_3 - \text{C}_6\text{H}_4)$	base	104.4
5						
181	Cl	H	H	$(\text{CH}_2)_3 - \underset{\text{CH}_2}{\underset{ }{\text{C}}}(\text{OH}) - (\text{2-thienyl})$	base	154.0
10						
182	Cl	H	H	$(\text{CH}_2)_3 - \underset{\text{CH}_2}{\underset{ }{\text{C}}}(\text{OH}) - (\text{3-Cl-C}_6\text{H}_4)$	base	121.7
15						
183	Cl	H	H	$(\text{CH}_2)_3 - \underset{\text{CH}_2}{\underset{ }{\text{C}}}(\text{H}) - (\text{3-F-C}_6\text{H}_4)$	base	91.5
20						
184	Cl	H	H	$(\text{CH}_2)_3 - \underset{\text{CH}_2}{\underset{ }{\text{C}}}(\text{OH}) - (\text{3-F-C}_6\text{H}_4)$	base	119.3
25						
185	Br	H	H	$(\text{CH}_2)_2 - \underset{(\text{CH}_2)_2}{\underset{ }{\text{N}}} - (\text{CH}_2)_3 - \text{C}_6\text{H}_5$	$\text{HC-COOH}$ $\text{HOOC-CH=}$	197.3
30						
186	Cl	H	H	$(\text{CH}_2)_3 - \underset{\text{CH}_2}{\underset{ }{\text{C}}}(\text{OH}) - [2,3-(\text{CH}_3)_2 - \text{C}_6\text{H}_3]$	base	183.7
187	Cl	H	H	$(\text{CH}_2)_3 - \underset{\text{CH}_2}{\underset{ }{\text{C}}}(\text{H}) - [2,3-(\text{CH}_3)_2 - \text{C}_6\text{H}_3]$	base	115.7
188	Cl	H	H	$(\text{CH}_2)_2 - \underset{\text{CH}_2}{\underset{ }{\text{C}}}(\text{OH}) - (\text{3-CH}_3 - \text{C}_6\text{H}_4)$	base	164.4
189	Cl	H	H	$(\text{CH}_2)_2 - \underset{\text{CH}_2}{\underset{ }{\text{C}}}=\text{C} - (\text{3-CH}_3 - \text{C}_6\text{H}_4)$	base	94.6

-48-

190	C1	H	H	$(\text{CH}_2)_2-\text{CH}-\text{(2-thienyl)}$ $\quad \quad \quad  $ $\quad \quad \quad (\text{CH}_2)_2$	base	127.0	
5	191	C1	H	H	$(\text{CH}_2)_3-\overset{\text{OH}}{\underset{\text{CH}_2}{\text{CH}}}-\text{(3-OCH}_3-\text{C}_6\text{H}_4)$	HCl	193.8
10	192	C1	H	H	$(\text{CH}_2)_3-\overset{\text{OH}}{\underset{\text{CH}_2}{\text{CH}}}-\text{(3-OCH}_3-\text{C}_6\text{H}_4)$	base	102.1
15	193	C1	H	H	$(\text{CH}_2)_3-\overset{\text{OH}}{\underset{\text{CH}_2}{\text{CH}}}-\text{(4-Cl,3-CF}_3-\text{C}_6\text{H}_3)$	base	129.8
20	194	C1	H	H	$(\text{CH}_2)_3-\overset{\text{CH}=\text{C}}{\underset{\text{CH}_2}{\text{CH}}}-\text{(3-F-C}_6\text{H}_4)$	base	121.5
25	195	C1	H	H	$(\text{CH}_2)_2-\overset{\text{OH}}{\underset{\text{CH}_2}{\text{C}}}-\text{(3-F-C}_6\text{H}_4)$	base	138.4
30	196	C1	H	H	$(\text{CH}_2)_2-\overset{\text{CH}}{\underset{\text{CH}_2}{\text{CH}}}-\text{(3-CH}_3-\text{C}_6\text{H}_4)$	base	74.7
35	197	C1	H	H	$(\text{CH}_2)_2-\overset{\text{OH}}{\underset{\text{CH}_2}{\text{CH}}}-\text{(4-Cl,3-CF}_3-\text{C}_6\text{H}_3)$	base	168.0
40	198	C1	H	H	$(\text{CH}_2)_2-\overset{\text{OH}}{\underset{\text{CH}_2}{\text{CH}}}-\text{(3-OCH}_3-\text{C}_6\text{H}_4)$	base	115.1
45	199	C1	H	H	$(\text{CH}_2)_2-\overset{\text{OH}}{\underset{\text{CH}_2}{\text{CH}}}-\text{(2-thienyl)}$	base	179.5

-49-

200	Cl	H	H	$(CH_2)_2 - CH - NH - COOC_2H_5$	base	157.9	
5	201	Cl	H	H	$(CH_2)_2 - CH - (2\text{-thienyl})$	base	119.3

Example 29

A mixture of 5.2 parts of 3,6-diiodopyridazine, 3.5 parts of 10 1-[3-(trifluoromethyl)phenyl]piperazine, 3.2 parts of sodium carbonate and 90 parts of N,N-dimethylacetamide was stirred and heated overnight at 70°C. The reaction mixture was poured onto water. The precipitated product was filtered off and crystallized from 2-propanol, yielding 3.2 parts (48%) of 3-iodo-6-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]-15 pyridazine; mp. 144.6°C (compound 202).

In a similar manner there were also prepared:

3-iodo-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine; mp. 163.1°C (compound 203);

3-[4-(3-chlorophenyl)-1-piperazinyl]-6-iodopyridazine; mp. 165.0°C 20 (compound 204);

3-[4-(2,3-dimethylphenyl)-1-piperazinyl]-6-iodopyridazine;  
mp. 179.4°C (compound 205); and

3-iodo-6-[4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]pyridazine;  
mp. 106.8°C (compound 206).

Example 30

A mixture of 4.6 parts of 1-[3-(trifluoromethyl)phenyl]piperazine, 6.4 parts of sodium carbonate and 160 parts of 4-methyl-2-pentanone was distilled azeotropically to dry. 3.3 Parts of 3,6-dichloropyridazine were added and the whole was stirred and refluxed for 48 hours using a 30 water separator. After cooling, water was added and the product was extracted with dichloromethane. The organic layer was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (99:1 by volume) as eluent. The pure fractions were collected and the eluent was

-50-

evaporated. The residue was crystallized from 2-propanol, yielding 2.6 parts (37.9%) of 3-chloro-6-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]pyridazine; mp. 149.4°C (compound 207).

Example 31

5 To a stirred solution of 7.5 parts of 3,6-dichloropyridazine in 75 parts of N,N-dimethylformamide was added dropwise a solution of 8 parts of ethyl 1-piperazinecarboxylate and 5.6 parts of N,N-diethylethanamine in 25 parts of N,N-dimethylformamide. Upon completion, the whole was stirred overnight at a temperature of about 50°C. After cooling, the 10 reaction mixture was poured onto water and the product was extracted with trichloromethane. The organic layer was dried, filtered and evaporated. The residue was crystallized from 2-propanol, yielding 3.6 parts of ethyl 4-(6-chloro-3-pyridazinyl)-1-piperazinecarboxylate; mp. 123.8°C (compound 208).

15 Example 32

A mixture of 3.2 parts of 3-chloro-6-(methylsulfonyl)pyridazine, 3 parts of 1-(3-methylphenyl)piperazine, 2 parts of N,N-diethylethanamine and 180 parts of benzene was stirred for 24 hours at reflux. The reaction mixture was evaporated. Water was added to the residue. The 20 precipitated product was filtered off, washed with water and dissolved in trichloromethane. The solution was dried, filtered and evaporated. The residue was crystallized from methanol. The product was filtered off and dried, yielding 5 parts (89%) of 3-[4-(3-methylphenyl)-1-piperazinyl]-6-(methylsulfonyl)pyridazine; mp. 201°C (compound 209).

25 In a similar manner there were also prepared:

3-[4-(3-methylphenyl)-1-piperazinyl]-6-(methylsulfinyl)pyridazine; mp. 146.9°C (compound 210);

3-[3,6-dihydro-4-(3-methylphenyl)-1(2H)-pyridinyl]-6-(methylsulfonyl)pyridazine; mp. 179.8°C (compound 211); and

30 3-[3,6-dihydro-4-(3-methylphenyl)-1(2H)-pyridinyl]-6-(methylsulfinyl)pyridazine; mp. 131.0°C (compound 212).

Example 33

A mixture of 3.3 parts of 3,6-dichloropyridazine, 3.3 parts of 1-(2-pyridinyl)piperazine, 1.5 parts of sodium hydrogencarbonate and 35 120 parts of ethanol was stirred and refluxed over weekend. The

-51-

reaction mixture was evaporated. Water was added to the residue and the product was extracted with dichloromethane. The extract was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (99:1 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from a mixture of 2-propanol and tetrahydrofuran, yielding 2.5 parts (45.3%) of 3-chloro-6-[4-(2-pyridinyl)-1-piperazinyl]pyridazine; mp. 194.7°C (compound 213).

10 Example 34

A mixture of 3.2 parts of 3-chloro-6-(methylthio)pyridazine, 3.14 parts of 1,2,3,6-tetrahydro-4-(3-methylphenyl)pyridine hydrochloride, 5.3 parts of sodium carbonate and 80 parts of 1-butanol was stirred for 48 hours at reflux temperature. The reaction mixture was evaporated. 15 Water was added. The product was extracted with trichloromethane. The extract was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (98:2 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from 2-propanol. The product was filtered off and dried, yielding 0.8 parts (18%) of 3-[3,6-dihydro-4-(3-methylphenyl)-1(2H)-pyridinyl]-6-(methylthio)pyridazine; mp. 129.8°C (compound 214).

Example 35

To a stirred solution of 300 parts of hexahydro-1H-1,4-diazepine in 25 900 parts of methylbenzene were added 75 parts of 3,6-dichloropyridazine. The whole was stirred and refluxed for 4 hours. The reaction mixture was evaporated. Water was added to the residue. The product was extracted with trichloromethane. The extract was dried, filtered and evaporated. The residue was converted into the 30 hydrochloride salt in 2-propanol and ethanol. The salt was filtered off and dried, yielding 28 parts (22%) of 1-(6-chloro-3-pyridazinyl)-

-52-

hexahydro-1*H*-1,4-diazepine monohydrochloride (compound 215).

In a similar manner there was also prepared:

1-(6-chloro-5-methyl-3-pyridazinyl)hexahydro-1*H*-1,4-diazepine as a residue (compound 216).

5 Example 36

A mixture of 3.9 parts of 3,6-dichloro-4,5-dimethylpyridazine, 4.2 parts of 1-(2,3-dimethylphenyl)piperazine and 2.94 parts of potassium carbonate was stirred and heated for 4 hours in an oil bath at 190°C. After cooling, the mixture was taken up in water and trichloromethane.

10 The organic layer was separated, dried, filtered and evaporated. The residue was crystallized from 2-propanol. The product was filtered off and dried, yielding 2 parts (30%) of 3-chloro-6-[4-(2,3-dimethylphenyl)-1-piperazinyl]-4,5-dimethylpyridazine; mp. 194.5°C (compound 217).

15 In a similar manner there were also prepared:

3-chloro-4,5-dimethyl-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine; mp. 172.9°C (compound 218); and

4-(3-methylphenyl)-1-(6-methyl-3-pyridazinyl)-4-piperidinol; mp. 131.5°C (compound 219).

20 Example 38

A mixture of 3.5 parts of *N*-(6-chloro-3-pyridazinyl)acetamide, 3.6 parts of 1-(3-methylphenyl)piperazine and 2.8 parts of potassium carbonate was stirred for 7 hours in an oil bath at 160°C. After cooling, trichloromethane and water were added. The layers were 25 separated. The organic layer was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (97:3 by volume) as eluent. The second fraction was collected and the eluent was evaporated. The residue was converted into the hydrochloride salt in 2-propanol and 30 2-propanone. The salt was filtered off and dried, yielding 0.5 parts (6.6%) of 6-[4-(3-methylphenyl)-1-piperazinyl]-3-pyridazinamine dihydrochloride; mp. 178.5°C (compound 220).

-53-

Example 38

A mixture of 4 parts of 6-chloro-3-(4-ethylphenoxy)pyridazine and 6 parts of 1-(3-methylphenyl)piperazine was stirred and heated for 3 hours in an oil bath at 110°C. The whole was allowed to stand over-night. Concentrate ammonium hydroxide and trichloromethane were added. The precipitate was filtered off and the filtrate was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (95:5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from 2,2'-oxybispropane. The product was filtered off and dried, yielding 1.7 parts (27%) of 3-(4-ethylphenoxy)-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine; mp. 106.6°C (compound 221).

Following the same procedure and using equivalent amounts of the appropriate starting materials, there were also prepared:

15      3-methyl-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine; mp. 152.9°C (compound 222); and  
3-[4-(3-methylphenyl)-1-piperazinyl]-6-(methylthio)pyridazine; mp. 145.0°C (compound 223).

Example 39

20      A mixture of 22 parts of ethyl 4-(6-chloro-5-methyl-3-pyridazinyl)-1-piperazinecarboxylate, 28 parts of potassium hydroxide and 160 parts of 1-butanol was stirred overnight at reflux temperature. The reaction mixture was evaporated. Water was added. The product was extracted with trichloromethane. The extract was dried, filtered and evaporated. 2,2'-Oxybispropane was added. The product was filtered off and dried, yielding 17 parts (100%) of 3-chloro-4-methyl-6-(1-piperazinyl)pyridazine (compound 224).

Example 40

30      A mixture of 6 parts of ethyl [1-(6-chloro-3-pyridazinyl)-4-piperidinyl]carbamate and 60 parts of concentrate hydrochloric acid was stirred and refluxed for 24 hours. The reaction mixture was evaporated. Water was added and the whole was treated with concentrate ammonium hydroxide. The product was extracted with trichloromethane. The extract was dried, filtered and evaporated, yielding 3.8 parts (82%) of

-54-

1-(6-chloro-3-pyridazinyl)-4-piperidinamine; mp. 260°C. (dec.)  
(compound 225).

Example 41

A mixture of 3.6 parts of 3-chloro-6-(1-piperazinyl)pyridazine  
5 monohydrochloride, 5.3 parts of sodium carbonate and 90 parts of  
N,N-dimethylacetamide was stirred for a while at 60°C. Then there were  
added 3 parts of (3-bromopropyl)benzene and the whole was stirred  
overnight at 60°C. The reaction mixture was poured into water. The  
product was filtered off and converted into the hydrochloride salt in  
10 2-propanol. The salt was filtered off and dried, yielding 3.2 parts  
(60%) of 3-chloro-6-[4-(3-phenylpropyl)-1-piperazinyl]pyridazine  
monohydrochloride; mp. 207.3°C (compound 226)

In a similar manner there were also prepared:

3-chloro-4-methyl-6-[4-(3-phenylpropyl)-1-piperazinyl]pyridazine  
15 monohydrochloride 1-butanol(1:1).monohydrate; mp. 187.2°C (compound 227);  
3-methoxy-6-[4-(3-phenylpropyl)-1-piperazinyl]pyridazine; mp. 78.4°C  
(compound 228);  
3-[4-(3-phenylpropyl)-1-piperazinyl]pyridazine dihydrochloride.  
monohydrate; mp. 209.0°C (compound 229); and  
20 1-acetyl-4-(6-chloro-3-pyridazinyl)piperazine; mp. 153.6°C  
(compound 230).

Example 42

A mixture of 3 parts of 3-chloro-6-(1-piperazinyl)pyridazine, 2  
parts of benzeneacetylaldehyde, 1 part of a solution of thiophene in  
25 methanol 4% and 200 parts of methanol was hydrogenated at normal  
pressure and at room temperature with 2 parts of platinum-on-charcoal  
catalyst 5%. After the calculated amount of hydrogen was taken up, the  
catalyst was filtered off and the filtrate was evaporated. The residue  
was crystallized from 2-propanol. The product was filtered off and  
30 dried, yielding 1.5 parts (33%) of 3-chloro-6-[4-(2-phenylethyl)-  
1-piperazinyl]pyridazine; mp. 140.0°C (compound 231).

In a similar manner there were also prepared:

3-(4-butyl-1-piperazinyl)-6-chloropyridazine (E)-2-butenedioate(1:1);  
mp. 188.2°C (compound 232);

-55-

3-chloro-6-(4-cyclohexyl-1-piperazinyl)pyridazine: mp. 187.2°C  
(compound 233); and  
1-(6-chloro-3-pyridazinyl)-N-(phenylmethyl)-4-piperidinamine:  
mp. 93.8°C (compound 234).

5 Example 43

A mixture of 4 parts of 1-(6-chloro-3-pyridazinyl)-4-(3-methoxyphenyl)-4-piperidinol, 80 parts of ethanol and 50 parts of a hydrochloric acid solution 6N was stirred for 6 hours at reflux temperature. The reaction mixture was evaporated. Water was added and the whole was treated with concentrate ammonium hydroxide. The product was extracted with trichloromethane. The extract was dried, filtered and evaporated. The residue was crystallized from 2-propanol. The product was filtered off and dried, yielding 2.5 parts (64%) of 3-chloro-6-[3,6-dihydro-4-(3-methoxyphenyl)-1(2H)-pyridinyl]pyridazine:  
15 mp. 126.4°C (compound 235).

Following the same procedure and using equivalent amounts of the appropriate starting materials, there were also prepared:

3-chloro-6-[4-(3-chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-pyridazine: mp. 133.9°C (compound 236);

20 3-chloro-6-(3,4-dihydro-5-phenyl-1(2H)-pyridinyl)pyridazine:  
mp. 146.0°C (compound 237);

3-chloro-6-[3,4-dihydro-5-(3-methylphenyl)-1(2H)-pyridinyl]pyridazine:  
mp. 160.0°C (compound 238);

3-chloro-6-[4-(3-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl]pyridazine:  
25 mp. 124.7°C (compound 239);

3-chloro-6-[4-(2,3-dimethylphenyl)-3,6-dihydro-1(2H)-pyridinyl]-pyridazine: mp. 144.2°C (compound 240);

3-chloro-6-[4-(3-chlorophenyl)-3,6-dihydro-5-methyl-1(2H)-pyridinyl]-pyridazine: mp. 88.5°C (compound 241);

30 3-chloro-6-[3,4-dihydro-5-[3-(trifluoromethyl)phenyl]-1(2H)-pyridinyl]pyridazine: mp. 163.2°C (compound 242);

3-chloro-6-[3,6-dihydro-5-[3-(trifluoromethyl)phenyl]-1(2H)-pyridinyl]pyridazine: mp. 112.5°C (compound 243);

3-chloro-6-[5-(3-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl]pyridazine:  
35 mp. 134.9°C (compound 244);

-56-

3-chloro-6-[3,4-dihydro-5-(3-methoxyphenyl)-1(2H)-pyridinyl]-pyridazine; mp. 129.1°C (compound 245);

3-chloro-6-[5-(2,3-dimethylphenyl)-3,4-dihydro-1(2H)-pyridinyl]-pyridazine; mp. 148.8°C (compound 246);

5 3-chloro-6-[3,6-dihydro-4-(2-naphthalenyl)-1(2H)-pyridinyl]pyridazine monohydrochloride hemihydrate; mp. 187.2°C (compound 247);

3-chloro-6-[3-(3-methylphenyl)-2H-pyrrol-1(5H)-yl]pyridazine; mp. 198.1°C (compound 248);

3-chloro-6-[2,3-dihydro-4-(3-methylphenyl)-1H-pyrrol-1-yl]pyridazine; 10 mp. 195.3°C (compound 249);

3-chloro-6-[3,6-dihydro-4-(2-phenylethyl)-1(2H)-pyridinyl]pyridazine; mp. 104.2°C (compound 250);

3-chloro-6-[5-[4-chloro-3-(trifluoromethyl)phenyl]-3,4-dihydro-1(2H)-pyridinyl]pyridazine; mp. 140.9°C (compound 251);

15 3-chloro-6-[3-(3-fluorophenyl)-2,3-dihydro-1H-pyrrol-1-yl]pyridazine; mp. 213.0°C (compound 252);

3-chloro-6-[3-(3-fluorophenyl)-2,5-dihydro-1H-pyrrol-1-yl]pyridazine; mp. 228.8°C (compound 253);

3-[3,6-dihydro-4-(3-methylphenyl)-1(2H)-pyridinyl]-6-methylpyridazine; 20 mp. 123.4°C (compound 254);

3-[3,6-dihydro-4-(3-methylphenyl)-1(2H)-pyridinyl]-6-methoxypyridazine; mp. 116.4°C (compound 255); and

3-butoxy-6-[3,6-dihydro-4-(3-methylphenyl)-1(2H)-pyridinyl]pyridazine; mp. 97.8°C (compound 256).

25 Example 44

To a stirred mixture of 80 parts of 1-butanol, 0.4 parts of sodium hydroxide and 0.94 parts of phenol were added 2.2 parts of 3-chloro-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine at 60°C. The whole was stirred and refluxed over weekend. The reaction mixture was evaporated.

30 The residue was crystallized from 2,2'-oxybispropane. The product was filtered off and dried, yielding 2 parts (64%) of 3-butoxy-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine; mp. 105.2°C (compound 257).

Example 45

To a stirred sodium methoxide solution, previously prepared starting 35 from 1.6 parts of sodium in 24 parts of methanol, were added 4 parts of

-57-

3-chloro-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine. The whole was stirred and refluxed for 40 hours. After cooling, 25 parts of water were added. The product was filtered off, washed with water and dissolved in trichloromethane. The organic layer was dried, filtered and evaporated. The residue was crystallized from a mixture of 2-propanol and 2,2'-oxybispropane. The product was filtered off and dried, yielding 2 parts (50%) of 3-methoxy-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine; mp. 137.1°C (compound 258).

Following the same procedure and using equivalent amounts of the appropriate starting materials, there were also prepared:

3-[4-(3-fluorophenyl)-3,4-dihydro-1(2H)-pyridinyl]-6-methoxypyridazine; mp. 85.2°C (compound 259);

3-[3,6-dihydro-4-(2,3-dimethylphenyl)-1(2H)-pyridinyl]-6-methoxy-pyridazine; mp. 110.8°C (compound 260);

15 1-(6-methoxy-3-pyridazinyl)-4-(3-methylphenyl)-4-piperidinol; mp. 125.6°C (compound 261);

3-[3,4-dihydro-4-(3-methylphenyl)-1(2H)-pyridinyl]-6-ethoxypyridazine; mp. 84.3°C (compound 262); and

1-(6-butoxy-3-pyridazinyl)-4-(3-methylphenyl)-4-piperidinol; 20 mp. 106.7°C (compound 263).

Example 46

A mixture of 1.9 parts of phenol, 2.9 parts of 3-chloro-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine and 2.76 parts of potassium carbonate was stirred and heated for 7 hours in an oil bath at 150°C. 25 After cooling, water was added. The product was extracted with trichloromethane. The extract was dried, filtered and evaporated. The residue was crystallized from a mixture of 2-propanol and 2,2'-oxybis-propane. The product was filtered off and dried, yielding 2 parts (60%) of 3-[4-(3-methylphenyl)-1-piperazinyl]-6-phenoxy-pyridazine; 30 mp. 123.4°C (compound 264).

In a similar manner there were also prepared:

3-(4-chlorophenoxy)-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine; mp. 130.1°C (compound 265); and

3-[4-(3-methylphenyl)-1-piperazinyl]-6-(phenylthio)pyridazine; 35 mp. 135.3°C (compound 266).

Example 47

To a stirred solution of 0.7 parts of sodium in 20 parts of benzenemethanol were added 5.8 parts of 3-chloro-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine. The whole was stirred and heated in 5 an oil bath at 180°C. After standing overnight, water was added and the product was extracted with trichloromethane. The extract was dried, filtered and evaporated. 2,2'-Oxybispropane was added to the residue. The product was filtered off and crystallized from a mixture of 2-propanol and methanol. The product was filtered off and dried, 10 yielding 3.4 parts (47%) of 3-[4-(3-methylphenyl)-1-piperazinyl]-6-(phenylmethoxy)pyridazine; mp. 159.4°C (compound 267).

In a similar manner there was also prepared:

4-(3-methylphenyl)-1-[6-(phenylmethoxy)-3-pyridazinyl]-4-piperidinol; mp. 124.8°C (compound 268).

Example 48

A mixture of 6.1 parts of 4-(3-methylphenyl)-1-[6-(phenylmethoxy)-3-pyridazinyl]-4-piperidinol and 250 parts of 2-methoxyethanol was hydrogenated at normal pressure and at room temperature with 2 parts of palladium-on-charcoal catalyst 10%. After the calculated amount of 20 hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated. The residue was boiled in 2-propanol. The product was filtered off and dried, yielding 4.5 parts (97%) of 6-[4-hydroxy-4-(3-methylphenyl)-1-piperidinyl]-3-pyridazinol; mp. 264.6°C (compound 269).

25 A mixture of 2.9 parts of 6-[4-hydroxy-4-(3-methylphenyl)-1-piperidinyl]-3-pyridazinol, 30 parts of a hydrochloric acid solution 6N and 24 parts of ethanol was stirred for 2 hours at reflux temperature. The reaction mixture was evaporated. Crushed ice was added and the whole was treated with concentrate ammonium hydroxide. The product was 30 extracted with trichloromethane. The extract was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (98:2 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from a mixture of 2-propanol 35 and 2,2'-oxybispropane. The product was filtered off and dried.

-59-

yielding 2 parts (75%) of 6-[3,6-dihydro-4-(3-methylphenyl)-1(2H)-pyridinyl]-3-pyridazinol; mp. 179.0°C (compound 270).

Example 49

A mixture of 6 parts of 3-[4-(3-methylphenyl)-1-piperazinyl]-6-5 (phenylmethoxy)pyridazine and 60 parts of concentrate hydrochloric acid was stirred and refluxed for 3 hours. The whole was allowed to stand overnight and treated with concentrate ammonium hydroxide. The product was filtered off, washed with water and dissolved in trichloromethane. The organic layer was dried, filtered and evaporated. The residue was 10 crystallized from a mixture of 2-propanol and 2,2'-oxybispropane. The product was filtered off and dried, yielding 4.5 parts (98%) of 6-[4-(3-methylphenyl)-1-piperazinyl]-3(2H)-pyridazinone; mp. 209.8°C (compound 271).

Example 50

15 A mixture of 7.3 parts of 3-chloro-6-[4-(4-methoxyphenyl)-1-piperazinyl]pyridazine, 2 parts of calcium oxide and 200 parts of methanol was hydrogenated at normal pressure and at room temperature with 2 parts of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen was taken up, the catalyst was filtered 20 off over Hyflo and the filtrate was evaporated. The residue was crystallized from 2-propanol, yielding 4.1 parts (63.2%) of 3-[4-(4-methoxyphenyl)-1-piperazinyl]pyridazine; mp. 133.4°C (compound 272).

Example 51

25 A mixture of 5.8 parts of 3-chloro-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine and 3 parts of thiourea was stirred for 3 hours in an oil bath at 165°C. After cooling, there were added 150 parts of a sodium hydroxide solution 0.5N. The whole was stirred and refluxed for 15 minutes. It was filtered while hot and the filtrate was neutralized 30 with acetic acid. The product was filtered off, washed with water and separated by column chromatography over silica gel using a mixture of trichloromethane and methanol (98.5:1.5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from a mixture of ethanol and tetrahydrofuran. The product 35 was filtered off and dried, yielding 1.3 parts (22.7%) of

-60-

6-[4-(3-methylphenyl)-1-piperazinyl]-3-pyridazinethiol; mp. 174.2°C  
(compound 273).

Example 52

To a stirred solution of 0.92 parts of sodium in 8 parts of methanol  
5 were added 45 parts of benzene. Methanol was distilled off and then 6.2  
parts of methyl 6-[4-(3-methylphenyl)-1-piperazinyl]-3-pyridazine-  
carboxylate and 3.5 parts of ethyl acetate in 45 parts of benzene were  
added. The whole was stirred and refluxed overnight. The reaction  
mixture was evaporated. 100 Parts of water were added. The mixture was  
10 acidified with 24 parts of concentrate hydrochloric acid, boiled for 2  
hours, cooled and treated with sodium hydrogen carbonate. The product  
was filtered off, washed with water and dissolved in trichloromethane.  
The solution was dried, filtered and evaporated. The residue was  
purified by column chromatography over silica gel using a mixture of  
15 trichloromethane and methanol (98:2 by volume) as eluent. The pure  
fractions were collected and the eluent was evaporated. The residue was  
crystallized from a mixture of 2-propanol and 2,2'-oxybispropane. The  
product was filtered off and dried, yielding 3 parts (51%) of  
1-[6-[4-(3-methylphenyl)-1-piperazinyl]-3-pyridazinyl]ethanone;  
20 mp. 135.9°C (compound 274).

In a similar manner there were also prepared:

1-[6-[3,6-dihydro-4-(3-methylphenyl)-1(2H)-pyridinyl]-3-pyridazinyl]-  
ethanone; mp. 115.0°C (compound 275).

25

30

35

C. Pharmacological examples.Example 53

In order to illustrate the useful anti-viral properties of the  
5 compounds of the present invention a number of such compounds were  
tested in the previously described Rhinovirus Cytopathic Effect  
Test. These compounds together with the results of the test are  
gathered in the following table.

10

15

20

25

30

35

Compound No.	lowest concentration in µg/ml
5	10
8	10
29	0.4
207	0.4
149	0.4
213	2
34	0.08
35	2
36	0.4
37	2
40	0.016
41	0.4
44	0.4
48	10
10	2
136	0.003
26	0.4
11	2
25	2
15	2
16	10

-62-

	18	0.4
	21	2
	56	0.4
5	57	2
	58	0.016
	257	10
	22	0.08
	24	2
10	146	0.4
	23	0.016
	60	0.016
	61	0.08
	148	0.08
15	63	0.016
	64	0.4
	203	0.003
	161	10
	66	2
20	67	10
	69	0.4
	218	0.4
	165	0.08
	166	10
25	77	0.08
	168	0.003
	170	2
	80	0.4
	204	0.003
30	266	10
	83	2
	171	10
	202	0.016
	84	0.016

-63-

	172	2
	173	2
	258	0.0006
5	142	0.016
	143	0.0006
	174	2
	86	10
	28	0.0006
10	175	0.0006
	88	0.003
	89	0.4
	90	0.016
	91	0.4
15	236	0.016
	93	0.08
	96	0.4
	238	2
	101	0.4
20	104	2
	222	0.08
	223	0.08
	241	0.016
	145	0.003
25	231	10
	112	0.08
	210	2
	113	10
	209	10
30	247	0.4
	274	10
	120	2
	250	0.4
	273	0.08
35	259	0.08

-64-

5

126	2
212	2
275	2

D. Composition Examples.

"Active ingredient" (A.I.) as used throughout the following examples relates to a compound of formula (I), a possible 10 stereochemically isomeric form or pharmaceutically acceptable acid addition salt thereof.

Example 54 : ORAL DROPS

500 Grams of the A.I. was dissolved in 0.5 liters of 2-hydroxy-propanoic acid and 1.5 liters of the polyethylene glycol at 60-80°C. 15 After cooling to 30-40°C there were added 35 liters of polyethylene glycol and the mixture was stirred well. Then there was added a solution of 1750 grams of sodium saccharin in 2.5 liters of purified water and while stirring there were added 2.5 liters of cocoa flavor and polyethylene glycol q.s. to a volume of 50 liters, providing an 20 oral drop solution comprising 10 milligrams of the A.I. per milliliter. The resulting solution was filled into suitable containers.

Example 55 : ORAL SOLUTION

9 Grams of methyl 4-hydroxybenzoate and 1 gram of propyl 4-hydroxybenzoate were dissolved in 4 liters of boiling purified 25 water. In 3 liters of this solution were dissolved first 10 grams of 2,3-dihydroxybutanedioic acid and thereafter 20 grams of the A.I. The latter solution was combined with the remaining part of the former solution and 12 liters 1,2,3-propanetriol and 3 liters of sorbitol 70% solution were added thereto. 40 Grams of sodium saccharin were 30 dissolved in 0.5 liters of water and 2 milliliters of raspberry and 2 milliliters of gooseberry essence were added. The latter solution was combined with the former, water was added q.s. to a volume of 20 liters providing an oral solution comprising 20 milligrams of the active ingredient per teaspoonful (5 milliliters). The resulting 35 solution was filled in suitable containers.

Example 56 : CAPSULES

20 Grams of the A.I., 6 grams sodium lauryl sulfate, 56 grams starch, 56 grams lactose, 0.8 grams colloidal silicon dioxide, and 1.2 grams magnesium stearate were vigorously stirred together. The 5 resulting mixture was subsequently filled into 1000 suitable hardened gelating capsules, comprising each 20 milligrams of the active ingredient.

Example 57 : FILM-COATED TABLETSPreparation of tablet core

10 A mixture of 100 grams of the A.I., 570 grams lactose and 200 grams starch was mixed well and thereafter humidified with a solution of 5 grams sodium dodecyl sulfate and 10 grams polyvinylpyrrolidone in about 200 milliliters of water. The wet powder mixture was sieved, dried and sieved again. Then there was added 100 grams microcrystalline cellulose and 15 grams hydrogenated vegetable oil. The whole was 15 mixed well and compressed into tablets, giving 10.000 tablets, each containing 10 milligrams of the active ingredient.

Coating

20 To a solution of 10 grams methyl cellulose in 75 milliliters of denatured ethanol there was added a solution of 5 grams of ethyl cellulose in 150 milliliters of dichloromethane. Then there were added 75 milliliters of dichloromethane and 2.5 milliliters 1,2,3-propanetriol. 10 Grams of polyethylene glycol was molten and dissolved in 75 milliliters of dichloromethane. The latter solution was added to the 25 former and then there were added 2.5 grams of magnesium octadecanoate, 5 grams of polyvinylpyrrolidone and 30 milliliters of concentrated colour suspension (Opaspray K-1-2109) and the whole was homogenated.

The tablet cores were coated with the thus obtained mixture in a coating apparatus.

Example 58 : INJECTABLE SOLUTION

30 1.8 Grams methyl 4-hydroxybenzoate and 0.2 grams propyl 4-hydroxybenzoate were dissolved in about 0.5 liters of boiling water for injection. After cooling to about 50°C there were added while stirring 4 grams lactic acid, 0.05 grams propylene glycol and 4 grams of the A.I. 35 The solution was cooled to room temperature and supplemented with

-66-

water for injection q.s. ad 1 liter volume, giving a solution of 4 milligrams A.I. per milliliters. The solution was sterilized by filtration (U.S.P. XVII p. 811) and filled in sterile containers.

Example 59 : SUPPOSITORIES

5      3 Grams A.I. was dissolved in a solution of 3 grams 2,3-dihydroxybutanedioic acid in 25 milliliters polyethylene glycol 400. 12 Grams surfactant and triglycerides q.s. ad 300 grams were molten together. The latter mixture was mixed well with the former solution. The thus obtained mixture was poured onto moulds at a temperature of 37-38°C to 10 form 100 suppositories each containing 30 milligrams of the active ingredient.

15

20


25

30

35

CLAIMS



1 1. A compound of formula



2 a pharmaceutically acceptable acid-addition salt and/or a  
3 possible stereochemically isomeric form and/or a possible tauto-  
4 meric form thereof, wherein

5  $R^1$  is a member selected from the group consisting of  
6 hydrogen, halo, 1H-imidazol-1-yl, lower alkyloxy, aryloxy,  
7 aryllower alkyloxy, lower alkylthio, arylthio, hydroxy, mercapto,  
8 amino, lower alkylsulfinyl, lower alkylsulfonyl, cyano, lower  
9 alkyloxycarbonyl, lower alkylcarbonyl, and lower alkyl;  
10  $R^2$  and  $R^3$  are, each independently, members selected from  
11 the group consisting of hydrogen and lower alkyl, or  $R^2$  and  $R^3$   
12 combined may form a bivalent radical of formula  $-CH=CH-CH=CH-$ ;  
13 A is a bivalent radical of formula:

14  $-CH=N-CH=CH-$  (a),



15 wherein one of the hydrogen atoms within the radical  $C_m H_{2m}$ ,  
16  $C_{m-1} H_{2(m-1)}$  or  $C_n H_{2n}$  may be replaced by lower alkyl or aryl;  
17 m and n are, each independently, integers of from 1 to 4 inclu-  
18 sive, the sum of m and n being 3, 4 or 5;

19      R<sup>4</sup> is a member selected from the group consisting of  
20     hydrogen; lower alkyl; aryl; thiazolyl; pyrimidinyl; quinolinyl;  
21     lower alkylcarbonyl; lower alkyloxycarbonyl; aryllower alkyl;  
22     diaryllower alkyl; phenyl being substituted with arylcarbonyl;  
23     pyridinyl, being optionally substituted with cyano or lower alkyl;  
24     cyclohexyl and cyclohexenyl both being optionally substituted with  
25     up to two substituents independently selected from the group  
26     consisting of cyano and aryl;  
27      R<sup>5</sup> is hydrogen; lower alkyl; aryl; hydroxy; lower alkyloxy;  
28     aryloxy; lower alkyloxy being substituted with morpholine,  
29     pyrrolidine or piperidine; amino; (lower alkyloxycarbonyl)amino;  
30     arylamino; (aryl)(lower alkyl)amino; (aryllower alkyl)amino;  
31     (aryllower alkenyl)amino; (aryllower alkenyl)(lower alkyl)amino;  
32     arylcarbonyloxy;  
33      R<sup>6</sup> is hydrogen; aryl; lower alkyl; (lower alkylcarbonyl  
34     amino)lower alkyl, aryllower alkyl; arylcarbonyllower alkyl;  
35     aminocarbonyl; arylcarbonyl; arylaminocarbonyl; (aryllower  
36     alkyl)carbonyl, lower alkyloxycarbonyl; indolyl; pyridinyl;  
37      R<sup>7</sup> and R<sup>8</sup> are, each independently, members selected from  
38     the group consisting of hydrogen, lower alkyl, aryl, aryllower  
39     alkyl and pyridinyl;  
40     wherein aryl is phenyl, being optionally substituted with up to  
41     3 substituents, each independently selected from the group  
42     consisting of halo, lower alkyl, trifluoromethyl, nitro, amino,  
43     lower alkyloxy, hydroxy and lower alkyloxycarbonyl; thienyl; and  
44     naphthalenyl.  
45     for use as a medicine.

1        2. A compound according to claim 1 for use as an anti-viral  
2        medicine.

1        3. A compound according to claim 2 for use as an anti-viral  
2        medicine against Rhinovirus infections.

1        4. A compound according to any one of claims 1 to 3, wherein  
2        R<sup>4</sup> is other than 3,3-diphenylpropyl when R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are

3 hydrogen radicals and A is a radical of formula (b);  
 4 -N A is other than piperidinyl, when R<sup>1</sup> is hydrogen and R<sup>2</sup>  
 5 and R<sup>3</sup> combined form a bivalent CH=CH-CH=CH radical;  
 6 -N A is other than piperidinyl and hexahydro-1H-azepinyl, when  
 7 R<sup>1</sup> is halo, R<sup>2</sup> is lower alkyl and R<sup>3</sup> is hydrogen;  
 8 R<sup>4</sup> is other than (dimethoxyphenyl)methyl, (dimethoxyphenyl)-  
 9 ethyl, α-methyl-phenethyl or (2-methylphenyl)methyl, when R<sup>1</sup>  
 10 is chloro and A is a radical of formula (b).

1 5. A compound according to any one of claims 1 to 3, wherein  
 2 A is a bivalent radical of formula (a), (c), (d) or



3 wherein m and n have the previously described meaning and one  
 4 of the hydrogen atoms within the radical C<sub>m</sub><sup>H</sup><sub>2m</sub>, C<sub>m-1</sub><sup>H</sup><sub>2(m-1)</sub> or  
 5 C<sub>n</sub><sup>H</sup><sub>2n</sub> may be replaced by lower alkyl or aryl; and  
 6 R<sup>4-C</sup> is a member selected from the group consisting of aryl;  
 7 thiazolyl; pyrimidinyl; quinolinyl; lower alkylcarbonyl, lower  
 8 alkyloxycarbonyl; aryllower alkyl; diaryllower alkyl; phenyl being  
 9 substituted with arylcarbonyl; pyridinyl, being optionally substituted  
 10 with cyano or lower alkyl; cyclohexyl and cyclohexenyl both being  
 11 optionally substituted with up to two substituents independently  
 12 selected from the group consisting of cyano and aryl; provided that  
 13 i) when A is a radical of formula (c) and R<sup>6</sup> is hydrogen,  
 14 then R<sup>5</sup> is other than hydrogen, hydroxy or lower alkyl;  
 15 ii) when R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are hydrogen radicals and A is a  
 16 radical of formula (b-1), then R<sup>4-C</sup> is other than 3,3-di-  
 17 phenylpropyl;  
 18 iii) when R<sup>2</sup> and R<sup>3</sup> are hydrogen radicals and A is a  
 19 radical of formula (a), then R<sup>1</sup> is other than halo;  
 20 iv) when R<sup>1</sup> is chloro, R<sup>2</sup> and R<sup>3</sup> are hydrogen radicals and  
 21 A is a radical of formula (b-1), then R<sup>4-C</sup> is other than  
 22 2-methoxyphenyl.  
 23 v) when R<sup>1</sup> is chloro, and A is a bivalent radical of

24 formula (b-1) then R<sup>4-C</sup> is other then (dimethoxyphenyl)-  
25 methyl, (dimethoxyphenyl)ethyl,  $\alpha$ -methyl-phenethyl or  
26 (2-methylphenyl)methyl.

1 6. A compound according to claim 5, wherein A is a bivalent  
2 radical of formula (b), wherein R<sup>4</sup> is aryl, pyridinyl,  
3 pyrimidinyl, lower alkyloxycarbonyl, aryllower alkyl, diaryllower  
4 alkyl, quinolinyl, or wherein A is a bivalent radical of formula  
5 (c), wherein R<sup>5</sup> is hydrogen, aryl, arylamino, (aryl)(lower  
6 alkyl)amino, hydroxy, indolyl and R<sup>6</sup> is hydrogen, aryl,  
7 arylcarbonyl, (arylcarbonyl)lower alkyl, or wherein A is a  
8 bivalent radical of formula (d).

1 7. A compound according to claim 6, wherein R<sup>2</sup> and R<sup>3</sup> are  
2 both hydrogen radicals.

1 8. A compound according to claim 7 wherein in the bivalent  
2 radical A having the formula (b) m is the integer 2 or 3 and n is  
3 2, in the radical A having the formula (c) m is the integer 1 or 2  
4 and n is the integer 2, and in the radical A of formula (d), m is  
5 the integer 1 or 2 and n is the integer 2.


1 9. A compound according to claim 8, wherein R<sup>1</sup> is halo,  
2 lower alkyloxy, aryloxy, lower alkylthio, arylthio and cyano.

1 10. A compound according to claim 9, wherein R<sup>1</sup> is halo.

1 11. A compound according to any one of claims 1 to 3 which is  
2 3-bromo-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine.

1 12. A compound according to any one of claims 1 to 3 which is  
2 3-chloro-6-[3,6-dihydro-4-(3-methylphenyl)-1(2H)-pyridinyl]-  
3 pyridazine.



1 13. A compound of formula



2 a pharmaceutically acceptable acid-addition salt and/or a  
 3 possible stereochemically isomeric form and/or a possible tauto-  
 4 meric form thereof, wherein

5  $R^1$  is a member selected from the group consisting of  
 6 hydrogen, halo, 1H-imidazol-1-yl, lower alkyloxy, aryloxy,  
 7 aryllower alkyloxy, lower alkylthio, arylthio, hydroxy, mercapto,  
 8 amino, lower alkylsulfinyl, lower alkylsulfonyl, cyano, lower  
 9 alkyloxycarbonyl, lower alkylcarbonyl, and lower alkyl;  
 10  $R^2$  and  $R^3$  are, each independently, members selected from  
 11 the group consisting of hydrogen and lower alkyl, or  $R^2$  and  $R^3$   
 12 combined may form a bivalent radical of formula  $-CH=CH-CH=CH-$ ;  
 13  $A^2$  is a bivalent radical of formula:

14  $-CH=N-CH=CH-$  (a).



15 wherein one of the hydrogen atoms within the radical  $C_m H_{2m}$ ,  
 16  $C_{m-1} H_{2(m-1)}$  or  $C_n H_{2n}$  may be replaced by lower alkyl or aryl;  
 17  $m$  and  $n$  are, each independently, integers of from 1 to 4 inclu-  
 18 sive, the sum of  $m$  and  $n$  being 3, 4 or 5;

19  $R^{4-C}$  is a member selected from the group consisting of aryl:  
 20 thiazolyl; pyrimidinyl; quinolinyl; lower alkylcarbonyl, lower  
 21 alkyloxycarbonyl; aryllower alkyl; diaryllower alkyl; phenyl being  
 22 substituted with arylcarbonyl; pyridinyl, being optionally substituted

23 with cyano or lower alkyl; cyclohexyl and cyclohexenyl both being  
24 optionally substituted with up to two substituents independently  
25 selected from the group consisting of cyano and aryl:  
26       <sup>5</sup> is hydrogen; lower alkyl; aryl; hydroxy; lower alkyloxy;  
27 aryoxy; lower alkyloxy being substituted with morpholine,  
28 pyrrolidine or piperidine; amino; (lower alkyloxycarbonyl)amino;  
29 arylamino; (aryl)(lower alkyl)amino; (aryllower alkyl)amino;  
30 (aryllower alkenyl)amino; (aryllower alkenyl)(lower alkyl)amino;  
31 arylcarbonyloxy;  
32       <sup>6</sup> is hydrogen; aryl; lower alkyl; (lower alkylcarbonyl  
33 amino)lower alkyl, aryllower alkyl; arylcarbonyllower alkyl;  
34 aminocarbonyl; arylcarbonyl; arylaminocarbonyl; (aryllower  
35 alkyl)carbonyl, lower alkyloxycarbonyl; indolyl; pyridinyl;  
36       <sup>7</sup> and <sup>8</sup> are, each independently, members selected from  
37 the group consisting of hydrogen, lower alkyl, aryl, aryllower  
38 alkyl and pyridinyl;  
39       wherein aryl is phenyl, being optionally substituted with up to  
40 3 substituents, each independently selected from the group  
41 consisting of halo, lower alkyl, trifluoromethyl, nitro, amino,  
42 lower alkyloxy, hydroxy and lower alkyloxycarbonyl; thiienyl; and  
43 naphthalenyl, provided that  
44 i) when A<sup>2</sup> is a radical of formula (c) and R<sup>6</sup> is hydrogen,  
45       then R<sup>5</sup> is other than hydrogen, hydroxy or lower alkyl;  
46 ii) when R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are hydrogen radicals and A<sup>2</sup> is a  
47       radical of formula (b-1), then R<sup>4-C</sup> is other than 3,3-di-  
48       phenylpropyl;  
49 iii) when R<sup>2</sup> and R<sup>3</sup> are hydrogen radicals and A<sup>2</sup> is a  
50       radical of formula (a), then R<sup>1</sup> is other than halo;  
51 iv) when R<sup>1</sup> is chloro, R<sup>2</sup> and R<sup>3</sup> are hydrogen radicals and  
52       A<sup>2</sup> is a radical of formula (b-1), then R<sup>4-C</sup> is other  
53       than 2-methoxyphenyl.  
54 v) when R<sup>1</sup> is chloro, and A<sup>2</sup> is a bivalent radical of  
55       formula (b-1) then R<sup>4-C</sup> is other than (dimethoxyphenyl)-  
56       methyl, (dimethoxyphenyl)ethyl,  $\alpha$ -methyl-phenethyl or  
57       (2-methylphenyl)methyl.

-73-

1        14. A compound according to claim 13, wherein  $A^2$  is a  
2 bivalent radical of formula (b-1), wherein  $R^{4-C}$  is aryl, pyri-  
3 dinyl, pyrimidinyl, lower alkyloxycarbonyl, aryllower alkyl, di-  
4 arylloweralkyl, quinolinyl, or wherein  $A^2$  is a bivalent radical  
5 of formula (c), wherein  $R^5$  is hydrogen, aryl, arylamino, (aryl)-  
6 (lower alkyl)amino, hydroxy, indolyl and  $R^6$  is hydrogen, aryl,  
7 arylcarbonyl, (arylcarbonyl)lower alkyl, or wherein  $A^2$  is a  
8 bivalent radical of formula (d).

1        15. A compound according to claim 14 wherein  $R^2$  and  $R^3$   
2 are both hydrogen radicals.

1        16. A compound according to claim 15 wherein in the  
2 bivalent radical  $A^2$  having the formula (b-1) m is the integer  
3 2 or 3 and n is 2, in the radical  $A^2$  having the formula (c) m is  
4 the integer 1 or 2 and n is the integer 2, and in the radical  $A^2$   
5 of formula (d), m is the integer 1 or 2 and n is the integer 2.

1        17. A compound according to claim 16 wherein  $R^1$  is halo.  
2 lower alkyloxy, aryloxy, lower alkylthio, arylthio and cyano.

1        18. A compound according to claim 17, wherein  $R^1$  is halo.

1        19. A compound selected from the group consisting of  
2 3-bromo-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine and the  
3 pharmaceutically acceptable acid addition salts thereof.

1        20. A compound selected from the group consisting of  
2 3-chloro-6-[3,6-dihydro-4-(3-methylphenyl)-1(2H)-pyridinyl]pyri-  
3 dazine and the pharmaceutically acceptable acid addition salts  
4 thereof.

1        21. A pharmaceutical composition comprising a suitable  
2 pharmaceutical carrier and as an active ingredient a  
3 therapeutically effective amount of a compound as defined in  
4 any one of claims 1 to 20.

-74-

1        22. An anti-viral pharmaceutical composition, comprising a  
 2        suitable pharmaceutical carrier and as an active ingredient an  
 3        anti-virally effective amount of a compound as defined in any one  
 4        of claims 1 to 20.

1        23. A method of preparing a pharmaceutical composition,  
 2        characterized in that a therapeutically effective amount of a  
 3        compound as defined in any of claims 1 to 20 is intimately  
 4        mixed with suitable pharmaceutical carriers.

1        24. A process for preparing a compound as defined in claim  
 2        13, characterized by  
 3        a) alkylating an amine of formula




4        with a pyridazine of formula



5        wherein W represents a reactive leaving group, if desired, in a  
 6        reaction-inert solvent, optionally in the presence of a base;

7        b) alkylating a pyridazinamine of formula




8        with a reagent of formula



9        wherein  $\text{R}^{4-\text{a}}$  is as  $\text{R}^4$ , provided that it is not hydrogen, and  
 10      W represents a reactive leaving group, if desired, in a  
 11      reaction-inert solvent, optionally in the presence of a base.

-75-


12 thus preparing a compound of formula



13 c) reductively N-alkylating a pyridazinamine of formula (I-a) with  
14 a carbonyl compound of formula

15  $(\text{R}^{4-\text{b}-1})=\text{C=O}$

16 said  $(\text{R}^{4-\text{b}-1})=\text{C=O}$  being a compound of formula  $\text{R}^{4-\text{b}}-\text{H}$ ,  
17 wherein a  $-\text{CH}_2$  radical is oxidized to a carbonyl radical, and  
18 wherein  $\text{R}^{4-\text{b}}$  is aryllower alkyl, diaryllower alkyl,  
19 cyclohexyl or cyclohexenyl, in a reaction-inert solvent, thus  
20 preparing a compound of formula



21 and, if desired, converting the compounds of formula (I") into  
22 a therapeutically active non-toxic acid-addition salt form by  
23 treatment with an appropriate acid, or, conversely, converting  
24 the acid-addition salt into the free base form with alkali;  
25 and/or preparing stereochemically isomeric forms thereof.



Europäisches Patentamt  
European Patent Office  
Office européen des brevets

(11) Publication number:

0 156 433

A3



(12)

## EUROPEAN PATENT APPLICATION

(21) Application number: 85200384.7

(22) Date of filing: 15.03.85

(51) Int. Cl. 4: C 07 D 237/20

C 07 D 237/22, C 07 D 237/24  
C 07 D 401/04, C 07 D 401/12  
C 07 D 401/14, C 07 D 403/04  
C 07 D 403/12, C 07 D 417/12  
C 07 D 409/14, A 61 K 31/50

(30) Priority: 26.03.84 US 593444  
15.02.85 US 702772

(43) Date of publication of application:  
02.10.85 Bulletin 85/40

(88) Date of deferred publication of search report: 23.07.86

(84) Designated Contracting States:  
AT BE CH DE FR GB IT LI LU NL SE

(71) Applicant: JANSEN PHARMACEUTICA N.V.  
Turnhoutsebaan 30  
B-2340 Beerse(BE)

(72) Inventor: Stokbroekx, Raymond Antoine  
Rode Kruisstraat 13  
B-2340 Beerse(BE)


(72) Inventor: van der Aa, Marcel Jozef Maria  
Kattenberg 139  
B-2469 Kasterlee(BE)

(72) Inventor: Willems, Josephus Maria  
Tweesprongd  
B-2360 Oud-<sup>+</sup>


(72) Inventor:uyens, reberns Maria  
Eksterstraat 24  
B-2440 Geel(BE)

(54) Anti-virally active pyridazinamines.

(57) Pyridazinamines of the formula



and their pharmaceutically acceptable acid addition salts and/or possible stereochemically isomeric forms and/or tautomeric forms for use as medicines in particular for use as anti-viral agents; pharmaceutical compositions containing such compounds as an active ingredient and a method of preparing such compositions; novel pyridazinamines of the



ula  
and a method of preparing said compounds.

EP 0 156 433 : A3

0156433



European Patent  
Office

## EUROPEAN SEARCH REPORT

EP 85 20 0384

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl 4)
D,A	EP-A-0 055 583 (PFIZER)  * Page 1, lines 34-38; claims *  ---	1,13- 17	C 07 D 237/20 C 07 D 237/22 C 07 D 237/24 C 07 D 401/04 C 07 D 401/12 C 07 D 401/14 C 07 D 403/12 C 07 D 403/04 C 07 D 417/12 C 07 D 409/14 A 61 K 31/50
D,A	US-A-2 985 657 (P.A. JANSSEN)  * Columns 1,2,7,8 *  ---	1,13, 21	
D,A	US-A-4 104 385 (G.Y. LESHER et al.)  * Columns 1,9,10 *  -----	1,13	
TECHNICAL FIELDS SEARCHED (Int. Cl 4)			
C 07 D 237/00 C 07 D 401/00 C 07 D 403/00			
The present search report has been drawn up for all claims			
Place of search	Date of completion of the search	Examiner	
THE HAGUE	21-04-1986	FRANCOIS J.C.L.	
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons B : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure B : intermediate document			